Tokushima University / Educator and Researcher Directory --- Kawano, Hiroshi

Field of Study

Subject of Study

Book / Paper

Book:

1.	Hiroshi Kawano and Yasuhiko Nishioka : 膠原病の肺病変, Nankodo, Apr. 2019.
2.	Jun Kishi, Hiroshi Kawano and Yasuhiko Nishioka : 強皮症, Sep. 2014.

Academic Paper (Judged Full Paper):

1.	Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Kozo Kagawa, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : A novel BRD4 degrader, ARV-825, attenuates lung fibrosis through senolysis and antifibrotic effect., Respiratory Investigation, Vol.61, No.6, 781-792, 2023. (Summary) These results suggest that ARV825 may impact the progressive and irreversible course of fibrotic lung diseases. (Keyword) Humans / Mice / Animals / Nuclear Proteins / Senotherapeutics / Transcription Factors / Lung / Idiopathic Pulmonary Fibrosis / Bleomycin / Collagen / Mice, Inbred C57BL / Cell Cycle Proteins (Link to Publication Site) ● Publication site (DOI): 10.1016/j.resinv.2023.08.003 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37741093 ● Search Scopus @ Elsevier (PMID): 37741093 ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2023.08.003 (DOI: 10.1016/j.resinv.2023.08.003, PubMed: 37741093)
2.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis., Respiratory Research, Vol.24, No.1, 148, 2023. (Summary) These findings suggest that targeting PLK1 may be a novel therapeutic approach for pulmonary fibrosis by inhibiting lung fibroblast proliferation without affecting lung epithelial cells. In addition, while in silico screening is useful, it is essential to fully determine the biological activities of candidates by wet-lab validation studies. (Keyword) Mice / Animals / Drug Repositioning / Thiophenes / Benzimidazoles / Lung / Idiopathic Pulmonary Fibrosis / Fibroblasts / Bleomycin (Tokushima University Institutional Repository) ● Metadata: 119057 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12931-023-02446-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37269004 ● Search Scopus @ Elsevier (PMID): 37269004 ● Search Scopus @ Elsevier (DOI): 10.1186/s12931-023-02446-x (Tokushima University Institutional Repository: 119057, DOI: 10.1186/s12931-023-02446-x, PubMed: 37269004)
3.	Kozo Kagawa, Seidai Satou, Kazuya Koyama, Takeshi Imakura, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Hirohisa Ogawa, Hiroshi Kawano and Yasuhiko Nishioka : The lymphocyte-specific protein tyrosine kinase-specific inhibitor A-770041 attenuates lung fibrosis via the suppression of TGF-β production in regulatory T-cells., PLoS ONE, Vol.17, No.10, e0275987, 2022. (Summary) These results suggest that Lck inhibition attenuated lung fibrosis by suppressing TGF-β production in Tregs and support the role of Tregs in the pathogenesis of lung fibrosis. (Keyword) Mice / Animals / pulmonary fibrosis / T-Lymphocytes, Regulatory / Transforming Growth Factor beta1 / Bleomycin / Transforming Growth Factor beta / Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / Mice, Inbred C57BL (Tokushima University Institutional Repository) ● Metadata: 118786 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0275987 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36301948 ● Search Scopus @ Elsevier (PMID): 36301948 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0275987 (Tokushima University Institutional Repository: 118786, DOI: 10.1371/journal.pone.0275987, PubMed: 36301948)
4.	Hitoshi Nishijima, Mizuki Sugita, Natsuka Umezawa, Naoki Kimura, Hirokazu Sasaki, Hiroshi Kawano, Yasuhiko Nishioka, Minoru Matsumoto, Takeshi Oya, Koichi Tsuneyama, Junko Morimoto and Mitsuru Matsumoto : Development of organ-specific autoimmunity by dysregulated Aire expression., Immunology and Cell Biology, Vol.100, No.5, 371-377, 2022. (Summary) cells expressing AIRE in the peripheral blood before the treatment but not during the remission phase treated with immunosuppressive drugs. Thus, not only loss of function of AIRE/Aire but also augmented and/or dysregulated expression of AIRE/Aire should be considered for the pathogenesis of organ-specific autoimmunity. We suggest that further analyses should be pursued to establish a novel link between organ-specific autoimmune disease and dysregulated AIRE expression in clinical settings. (Keyword) Animals / autoimmunity / Clonal Deletion / Encephalomyelitis, Autoimmune, Experimental / female / Humans / Immune Tolerance / Mice / Myelin-Oligodendrocyte Glycoprotein / Thymus Gland (Tokushima University Institutional Repository) ● Metadata: 117817 (Link to Publication Site) ● Publication site (DOI): 10.1111/imcb.12546 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35313042 ● Search Scopus @ Elsevier (PMID): 35313042 ● Search Scopus @ Elsevier (DOI): 10.1111/imcb.12546 (Tokushima University Institutional Repository: 117817, DOI: 10.1111/imcb.12546, PubMed: 35313042)
5.	Tamotsu Tanaka, Kazuya Koyama, Naoko Takahashi, Katsuya Morito, Hanif Ali, Momoyo Azuma, Kozo Kagawa, Hiroshi Kawano, Rumana Yesmin, Mutsumi Aihara and Yasuhiko Nishioka : Lysophosphatidic acid, ceramide 1-phosphate and sphingosine 1-phosphate in peripheral blood of patients with idiophathic pulmonary fibrosis, The Journal of Medical Investigation : JMI, Vol.69, No.3.4, 196-203, 2022. (Summary) Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonias. Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are signaling lipids that evoke growth factor-like responses to many cells. Recent studies revealed the involvement of LPA and S1P in the pathology of IPF. In this study, we determined LPA, S1P and ceramide 1-phosphate (C1P) in peripheral blood plasma of IPF patients, and examined correlation to the vital capacity of lung (VC), an indicator of development of fibrosis. Blood plasma samples were taken from eleven patients with IPF and seven healthy volunteers. The lipids of the sample were extracted and subjected to liquid chromatography-tandem mass spectrometry for analysis. Results showed that there is a significant negative correlation between VC and plasma LPA levels, indicating that IPF patients with advanced fibrosis had higher concentration of LPA in their plasma. Average of S1P levels were significantly higher in IPF patients than those in healthy subjects. Although it is not statistically significant, a similar correlation trend that observed in LPA levels also found between VC and S1P levels. These results indicated that plasma LPA and S1P may be associated with deterioration of pulmonary function of IPF patients. J. Med. Invest. 69 : 196-203, August, 2022. (Keyword) Ceramides / Fibrosis / Humans / Idiopathic Pulmonary Fibrosis / Lysophospholipids / Sphingosine (Tokushima University Institutional Repository) ● Metadata: 117621 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.196 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244770 ● Search Scopus @ Elsevier (PMID): 36244770 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.196 (Tokushima University Institutional Repository: 117621, DOI: 10.2152/jmi.69.196, PubMed: 36244770)
6.	Hirokazu Ogino, Makoto Tobiume, Kozo Kagawa, Hiroshi Kawano, Satoshi Sakaguchi, Atsuro Saijo, Daisuke Matsumoto, Hiromitsu Takizawa, Yuriko Morikawa, Yoshimi Bando, Hisatsugu Goto, Hiroshi Nokihara and Yasuhiko Nishioka : A Case of Radiation-associated Angiosarcoma Presenting as Massive Pleural Effusion., Internal Medicine, Vol.61, No.9, 1393-1397, 2021. (Summary) A 67-year-old man was admitted to our hospital for massive pleural effusion. He had a history of mandibular gingival carcinoma treated with radiation therapy (RT). Based on the cytology findings of pleural effusion and a thoracoscopic pleural biopsy, we finally diagnosed him with radiation-associated angiosarcoma. Retrospective cell-block immunocytochemistry with pleural effusion also showed potential utility for the diagnosis. This case highlights the importance of considering the possibility of radiation-associated secondary cancer in patients with pleural effusion who have a history of RT. (Keyword) Aged / Biopsy / Hemangiosarcoma / Humans / male / Pleural Effusion / Retrospective Studies / Thoracoscopy (Tokushima University Institutional Repository) ● Metadata: 118013 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.8195-21 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34645765 ● Search Scopus @ Elsevier (PMID): 34645765 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.8195-21 (Tokushima University Institutional Repository: 118013, DOI: 10.2169/internalmedicine.8195-21, PubMed: 34645765)
7.	Takeshi Imakura, Seidai Satou, Tetsu Tomonari, Kojin Murakami, Naoki Takahashi, Nobuhito Naito, Masato Mima, Kozo Kagawa, Kazuya Koyama, Haruka Nishimura, Hiroshi Kawano, Hiroshi Nokihara, Masahiko Azuma, Tetsuji Takayama and Yasuhiko Nishioka : Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma., Internal Medicine, Vol.61, No.8, 1211-1217, 2021. (Summary) Lenvatinib is a multi-targeted tyrosine kinase inhibitor available for the treatment of unresectable hepatocellular carcinoma (HCC). We herein report an 84-year-old-man with interstitial pneumonia caused by lenvatinib. Four months after the start of lenvatinib administration for HCC, chest computed tomography revealed bilateral ground-glass opacity. However, he continued to take lenvatinib for four more months until he complained of dyspnea on exertion. This is a case of lenvatinib-induced interstitial pneumonia that progressed relatively slowly with a long asymptomatic period despite the appearance of pneumonia on image findings. (Keyword) Aged, 80 and over / Carcinoma, Hepatocellular / Humans / Liver Neoplasms / Lung Diseases, Interstitial / male / Phenylurea Compounds / Quinolines (Tokushima University Institutional Repository) ● Metadata: 118011 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.7300-21 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34544944 ● Search Scopus @ Elsevier (PMID): 34544944 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.7300-21 (Tokushima University Institutional Repository: 118011, DOI: 10.2169/internalmedicine.7300-21, PubMed: 34544944)
8.	Hiroshi Kawano, Kazuya Koyama, Haruka Nishimura, Yuko Toyoda, Kozo Kagawa, Seidai Satou, Nobuhito Naito, Hisatsugu Goto, Yutaka Inagaki and Yasuhiko Nishioka : Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain., Immunity, Inflammation and Disease, Vol.9, No.1, 120-127, 2020. (Summary) Our findings suggest that the improved method can be a useful for the detection of pure lung fibrocytes and allows us to further analyze the characteristics of viable fibrocytes. (Tokushima University Institutional Repository) ● Metadata: 116531 (Link to Publication Site) ● Publication site (DOI): 10.1002/iid3.361 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33369271 ● Search Scopus @ Elsevier (PMID): 33369271 ● Search Scopus @ Elsevier (DOI): 10.1002/iid3.361 (Tokushima University Institutional Repository: 116531, DOI: 10.1002/iid3.361, PubMed: 33369271)
9.	Nobuhito Naito, Hiroshi Kawano, Yuya Yamashita, Mayo Kondou, Shotaro Haji, Ryosuke Miyamoto, Yuko Toyoda, Yasuhisa Kanematsu, Yuishin Izumi, Yoshimi Bando and Yasuhiko Nishioka : Neuropsychiatric systemic lupus erythematosus with cerebellar vasculitis and obstructive hydrocephalus requiring decompressive craniectomy., Modern Rheumatology Case Reports, Vol.5, No.1, 52-57, 2020. (Summary) A 36-year-old woman who had been diagnosed with systemic lupus erythematosus (SLE) was admitted to our hospital due to increasing disease SLE activity. Despite the intensification of immunosuppressive treatment, headache newly developed and worsened. Magnetic resonance imaging (MRI) revealed spreading of a high-intensity area along the sulci of the bilateral cerebellar hemispheres. She was diagnosed with neuropsychiatric SLE and methylprednisolone (mPSL) pulse therapy was started. However, consciousness disorder due to cerebellar oedema with obstructive hydrocephalus appeared and required decompressive craniectomy. The histological findings of the biopsy specimens from cerebellar vermis were compatible with features of vasculitis. She was successfully treated adding intravenous cyclophosphamide therapy. (Link to Publication Site) ● Publication site (DOI): 10.1080/24725625.2020.1826626 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33021438 ● Search Scopus @ Elsevier (PMID): 33021438 ● Search Scopus @ Elsevier (DOI): 10.1080/24725625.2020.1826626 (DOI: 10.1080/24725625.2020.1826626, PubMed: 33021438)
10.	Shun Morizumi, Seidai Satou, Kazuya Koyama, Hiroyasu Okazaki, Yajuan Chen, Hisatsugu Goto, Kozo Kagawa, Hirohisa Ogawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara and Yasuhiko Nishioka : Blockade of Pan-Fibroblast Growth Factor Receptors Mediates Bidirectional Effects in Lung Fibrosis., American Journal of Respiratory Cell and Molecular Biology, Vol.63, No.3, 317-326, 2020. (Summary) H]thymidine incorporation assays. The expression of FGFR was analyzed using IB or flow cytometry. We also investigated the effect of BGJ398 on pulmonary fibrosis induced by bleomycin in mice. Both lung fibroblasts and AECs expressed FGFRs. BGJ398 significantly inhibited the proliferation and migration of lung fibroblasts stimulated with FGF2. BGJ398 also reduced the proliferation of AECs in response to FGF2. Although the administration of BGJ398 ameliorated pulmonary fibrosis in bleomycin-treated mice, it increased mortality resulting from alveolar injury and inhibition of AEC regeneration. These data suggest that the total inhibition of FGFR signaling can suppress lung fibrosis by inhibiting fibroblast activities, although alveolar injury is simultaneously caused. (Keyword) Alveolar Epithelial Cells / Animals / Bleomycin / Fibroblasts / Humans / Idiopathic Pulmonary Fibrosis / Indoles / Lung / Mice / phosphorylation / Receptors, Fibroblast Growth Factor / signal transduction (Tokushima University Institutional Repository) ● Metadata: 115073 (Link to Publication Site) ● Publication site (DOI): 10.1165/rcmb.2019-0090OC (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32338990 ● Search Scopus @ Elsevier (PMID): 32338990 ● Search Scopus @ Elsevier (DOI): 10.1165/rcmb.2019-0090OC (Tokushima University Institutional Repository: 115073, DOI: 10.1165/rcmb.2019-0090OC, PubMed: 32338990)
11.	Shuichi Abe, Seidai Satou, Yoshinori Aono, Momoyo Azuma, Masami Kishi, Koyama Kazuya, Takahashi Naoki, Kozo Kagawa, Hiroshi Kawano and Yasuhiko Nishioka : Functional analysis of human fibrocytes derived from monocytes reveals their profibrotic phenotype through paracrine effects, The Journal of Medical Investigation : JMI, Vol.67, No.1.2, 102-112, 2020. (Summary) Fibrocytes, which are bone marrow-derived collagen-producing cells, were reported to play a role in the pathogenesis of pulmonary fibrosis. However, their function in pulmonary fibrosis is unclear. We analyzed their function compared with that of monocytes and localization in fibrotic tissues in patients with idiopathic pulmonary fibrosis (IPF). We compared the gene expression profile of monocyte-derived fibrocytes with that of monocytes by microarray analysis. Proliferation and differentiation into myofibroblasts were examined by 3H-thymidine incorporation assay and Western blotting. We measured the level of growth factors in the culture supernatant of fibrocytes by ELISA. The localization of fibrocytes in lung tissues of patients with IPF was determined by immunofluorescence staining. Compared with monocytes, fibrocytes had higher expression of extracellular matrix- and growth factor-encoding genes, including PDGF-B, FGF-2 and VEGF-B. Although fibrocytes did not proliferate in response to PDGF, co-culture of fibrocytes stimulated the growth of lung fibroblasts through the production of PDGF-BB. In the lung of IPF patients, CD45+Collagen-I+FSP-1+ cells, which have a similar phenotype to fibrocytes, were detected and co-stained with anti-PDGF antibody. This study suggested that fibrocytes function in pulmonary fibrosis partly by producing PDGF in the lungs of IPF patients. J. Med. Invest. 67 : 102-112, February, 2020. (Tokushima University Institutional Repository) ● Metadata: 114734 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.102 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378592 ● Search Scopus @ Elsevier (PMID): 32378592 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.102 (Tokushima University Institutional Repository: 114734, DOI: 10.2152/jmi.67.102, PubMed: 32378592)
12.	Takeshi Imakura, Yuko Toyoda, Seidai Satou, Kazuya Koyama, Haruka Nishimura, Kozo Kagawa, Naoki Takahashi, Nobuhito Naito, Kojin Murakami, Hiroshi Kawano, Masahiko Azuma, Tsutomu Shinohara and Yasuhiko Nishioka : Distinct improvement of pulmonary function, ground-glass opacity, hypoxia and physical findings in an idiopathic pulmonary fibrosis patient after pirfenidone treatment : a case report with a review of the literature., The Journal of Medical Investigation : JMI, Vol.67, No.3.4, 358-361, 2020. (Summary) Background : Pirfenidone (PFD), an anti-fibrosis drug for idiopathic pulmonary fibrosis (IPF), suppresses disease progression and delays decline of forced vital capacity. However, this drug rarely makes marked improvement of pulmonary function, chest high-resolution computed tomography (HRCT) findings and hypoxia. Case presentation : A 59 year-old-man, who was a former smoker and had a history of alcoholic liver cirrhosis, developed exertional dyspnea and was referred to our hospital. HRCT showed honeycomb changes with surrounding ground-glass opacity (GGO) in a predominantly basal and subpleural distribution. He was diagnosed with IPF and the treatment with PFD was started. At 16 months after the start of treatment, the predicted forced vital capacity value markedly improved from 82.9% to 98.6%. His resting-state partial pressure of arterial oxygen while breathing room air increased from a minimum of 54.7 mmHg (at 2 months treatment) to 72.5 mmHg. The GGO observed at diagnosis disappeared in HRCT. But after 32 months of treatment, his general condition got worse gradually, and he died from chronic progression of IPF after 48 months of treatment. Conclusion : Our case suggests that a complication of chronic liver disease and the existence of GGO may be characteristics of super-responder to PFD treatment for IPF patients. J. Med. Invest. 67 : 358-361, August, 2020. (Tokushima University Institutional Repository) ● Metadata: 115454 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.358 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33148916 ● Search Scopus @ Elsevier (PMID): 33148916 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.358 (Tokushima University Institutional Repository: 115454, DOI: 10.2152/jmi.67.358, PubMed: 33148916)
13.	Hiroyasu Okazaki, Seidai Satou, Kazuya Koyama, Shun Morizumi, Shuichi Abe, Momoyo Azuma, Yajuan Chen, Hisatsugu Goto, Yoshinori Aono, Hirohisa Ogawa, Kozo Kagawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara, Hiroyuki Kouji and Yasuhiko Nishioka : The novel inhibitor PRI-724 for Wnt/β-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice., Experimental Lung Research, Vol.45, No.7, 188-199, 2019. (Summary) These results suggest that the β-catenin/CBP inhibitor PRI-724 is a potent antifibrotic agent that acts by modulating the activity of macrophages in the lungs. (Tokushima University Institutional Repository) ● Metadata: 113984 (Link to Publication Site) ● Publication site (DOI): 10.1080/01902148.2019.1638466 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31298961 ● Summary page in Scopus @ Elsevier: 2-s2.0-85068899202 (Tokushima University Institutional Repository: 113984, DOI: 10.1080/01902148.2019.1638466, PubMed: 31298961, Elsevier: Scopus)
14.	Yuko Toyoda, Kazuya Koyama, Hiroshi Kawano, Haruka Nishimura, Kozo Kagawa, Shun Morizumi, Nobuhito Naito, Seidai Satou, Yuya Yamashita, Naoki Takahashi, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka : Clinical features of interstitial pneumonia associated with systemic lupus erythematosus., Respiratory Investigation, Vol.57, No.5, 435-443, 2019. (Summary) In SLE cases, IP primarily occurred in male and elderly patients. In addition to the NSIP pattern, the UIP pattern was evident on HRCT scans of IP-related SLE. The survival of SLE patients was unrelated to IP. (Keyword) Adult / Age of Onset / Aged / Disease Progression / Female / Humans / Incidence / Lung Diseases, Interstitial / Lupus Erythematosus, Systemic / Male / Middle Aged / Retrospective Studies / Sex Factors / Tomography, X-Ray Computed / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1016/j.resinv.2019.04.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31235450 ● Search Scopus @ Elsevier (PMID): 31235450 ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2019.04.005 (DOI: 10.1016/j.resinv.2019.04.005, PubMed: 31235450)
15.	Masaki Hanibuchi, Akira Kanoh, Takuya Kuramoto, Tatsuro Saito, Makoto Tobiume, Atsuro Saijo, Hiroyuki Kozai, Mayo Kondou, Shun Morizumi, Hiroto Yoneda, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Kenji Otsuka, Yuko Toyoda, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : Development, validation, and comparison of gene analysis methods for detecting mutation from non-small cell lung cancer patients-derived circulating free DNA., Oncotarget, Vol.10, No.38, 3654-3666, 2019. (Tokushima University Institutional Repository) ● Metadata: 115668 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.26951 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31217900 ● Search Scopus @ Elsevier (PMID): 31217900 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.26951 (Tokushima University Institutional Repository: 115668, DOI: 10.18632/oncotarget.26951, PubMed: 31217900)
16.	Kazuya Koyama, Hisatsugu Goto, Shun Morizumi, Kozo Kagawa, Haruka Nishimura, Seidai Satou, Hiroshi Kawano, Yuko Toyoda, Hirohisa Ogawa, Sakae Homma and Yasuhiko Nishioka : The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice., American Journal of Respiratory Cell and Molecular Biology, Vol.60, No.4, 478-487, 2019. (Summary) The signaling pathways of growth factors, including platelet-derived growth factor, can be considered specific targets for overcoming the poor prognosis of idiopathic pulmonary fibrosis. Nintedanib, the recently approved multiple kinase inhibitor, has shown promising antifibrotic effects in patients with idiopathic pulmonary fibrosis; however, its efficacy is still limited, and in some cases, treatment discontinuation is necessary owing to toxicities such as gastrointestinal disorders. Therefore, more effective agents with less toxicity are still needed. TAS-115 is a novel multiple tyrosine kinase inhibitor that preferably targets platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor, and c-FMS in addition to other molecules. In this study, we evaluated the antifibrotic effect of TAS-115 on pulmonary fibrosis in vitro and in vivo. TAS-115 inhibited the phosphorylation of PDGFR on human lung fibroblast cell line MRC-5 cells and suppressed their platelet-derived growth factor-induced proliferation and migration. Furthermore, TAS-115 inhibited the phosphorylation of c-FMS, a receptor of macrophage colony-stimulating factor, in murine bone marrow-derived macrophages and decreased the production of CCL2, another key molecule for inducing pulmonary fibrosis, under the stimulation of macrophage colony-stimulating factor. Importantly, the inhibitory effects of TAS-115 on both PDGFR and c-FMS were 3- to 10-fold higher than those of nintedanib. In a mouse model of bleomycin-induced pulmonary fibrosis, TAS-115 significantly inhibited the development of pulmonary fibrosis and the collagen deposition in bleomycin-treated lungs. These data suggest that strong inhibition of PDGFR and c-FMS by TAS-115 may be a promising strategy for overcoming the intractable pathogenesis of pulmonary fibrosis. (Keyword) Animals / Bleomycin / Cell Line / Cell Movement / Cell Proliferation / Humans / Male / Mice / Mice, Inbred C57BL / Phosphorylation / Protein Kinase Inhibitors / Pulmonary Fibrosis / Quinolines / Receptor, Macrophage Colony-Stimulating Factor / Receptors, Platelet-Derived Growth Factor / Receptors, Vascular Endothelial Growth Factor / Thiourea (Link to Publication Site) ● Publication site (DOI): 10.1165/rcmb.2018-0098OC (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30540913 ● Search Scopus @ Elsevier (PMID): 30540913 ● Search Scopus @ Elsevier (DOI): 10.1165/rcmb.2018-0098OC (DOI: 10.1165/rcmb.2018-0098OC, PubMed: 30540913)
17.	Hirokazu Ogino, Masaki Hanibuchi, Satoshi Sakaguchi, Yuko Toyoda, Toshifumi Tezuka, Hiroshi Kawano, Soji Kakiuchi, Kenji Otsuka, Atsuro Saijo, Masahiko Azuma, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : The clinical features of older patients with lung cancer in comparison with their younger counterparts., Respiratory Investigation, Vol.57, No.1, 40-48, 2019. (Summary) We should positively consider standard treatments for older patients. However, not only their shorter life expectancy but also their poor PS and multiple comorbidities that sometimes render patients unable to receive standard treatments and several chemotherapy regimens, make their prognosis poor. The standard treatments for older patients, especially in locally advanced stages, require modification. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.resinv.2018.10.003 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30448243 ● Search Scopus @ Elsevier (PMID): 30448243 ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2018.10.003 (DOI: 10.1016/j.resinv.2018.10.003, PubMed: 30448243)
18.	Masami Kishi, Yoshinori Aono, Seidai Satou, Kazuya Koyama, Momoyo Azuma, Shuichi Abe, Hiroshi Kawano, Jun Kishi, Yuko Toyoda, Hiroyasu Okazaki, Hirohisa Ogawa, Hisanori Uehara and Yasuhiko Nishioka : Blockade of platelet-derived growth factor receptor-β, not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice., PLoS ONE, Vol.13, No.12, 2018. (Summary) Platelet-derived growth factor (PDGF) has been implicated in the pathogenesis of pulmonary fibrosis. Nintedanib, a multi-kinase inhibitor that targets several tyrosine kinases, including PDGF receptor (PDGFR), was recently approved as an anti-fibrotic agent to reduce the deterioration of FVC in patients with idiopathic pulmonary fibrosis (IPF). However, the effects of PDGFR-α or -β on pulmonary fibrosis remain unclear. In an attempt to clarify their effects, we herein used blocking antibodies specific for PDGFR-α (APA5) and -β (APB5) in a bleomycin (BLM)-induced pulmonary fibrosis mouse model. The effects of these treatments on the growth of lung fibroblasts were examined using the 3H-thymidine incorporation assay in vitro. The anti-fibrotic effects of these antibodies were investigated with the Ashcroft score and collagen content of lungs treated with BLM. Their effects on inflammatory cells in the lungs were also analyzed using bronchoalveolar lavage fluid. We investigated damage to epithelial cells and the proliferation of fibroblasts in the lungs. APA5 and APB5 inhibited the phosphorylation of PDGFR-α and -β as well as the proliferation of lung fibroblasts induced by PDGF-AA and BB. The administration of APB5, but not APA5 effectively inhibited BLM-induced pulmonary fibrosis in mice. Apoptosis and the proliferation of epithelial cells and fibroblasts were significantly decreased by the treatment with APB5, but not by APA5. The late treatment with APB5 also ameliorated fibrosis in lungs treated with BLM. These results suggest that PDGFR-α and -β exert different effects on BLM-induced pulmonary fibrosis in mice. A specific approach using the blocking antibody for PDGFR-β may be useful for the treatment of pulmonary fibrosis. (Tokushima University Institutional Repository) ● Metadata: 113268 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0209786 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30596712 ● Search Scopus @ Elsevier (PMID): 30596712 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0209786 (Tokushima University Institutional Repository: 113268, DOI: 10.1371/journal.pone.0209786, PubMed: 30596712)
19.	Masaki Hanibuchi, Soji Kakiuchi, Shinji Atagi, Fumitaka Ogushi, Eiji Shimizu, Takashi Haku, Yuko Toyoda, Masahiko Azuma, Mayo Kondo, Hiroshi Kawano, Kenji Otsuka, Satoshi Sakaguchi, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease., Lung Cancer, Vol.125, 93-99, 2018. (Summary) This is the first prospective study designed to evaluate the efficacy of a specific chemotherapeutic regimen as the primary endpoint in patients with advanced NSCLC with ILD. The combination of S-1 with CBDCA may be a treatment option for advanced NSCLC patients with ILD (The clinical trial registration number: UMIN000011046). (Link to Publication Site) ● Publication site (DOI): 10.1016/j.lungcan.2018.09.007 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30429044 ● Search Scopus @ Elsevier (PMID): 30429044 ● Search Scopus @ Elsevier (DOI): 10.1016/j.lungcan.2018.09.007 (DOI: 10.1016/j.lungcan.2018.09.007, PubMed: 30429044)
20.	Hiroyuki Kozai, Yuko Toyoda, Hisatsugu Goto, Jun Kishi, Makoto Tobiume, Yuya Yamashita, Haruka Nishimura, Mayo Kondou, Hiroshi Kawano and Yasuhiko Nishioka : A case of interstitial pneumonia associated with anti-PL-7 antibody in a patient with rheumatoid arthritis., The Journal of Medical Investigation : JMI, Vol.65, No.1,2, 147-150, 2018. (Summary) A 65-year-old female had been treated rheumatoid arthritis (RA), interstitial pneumonia (IP) and nephrotic syndrome with prednisolone and cyclosporine. She was emergently admitted to our hospital due to the worsening exertional dyspnea and severe hypoxemia. Chest computed tomography (CT) showed new diffuse ground-glass opacities (GGOs) with slight consolidations along with bronchovascular bundle were observed in addition to pre-existing reticular shadows in both lungs with lower lobe-predominance. An acute exacerbation (AE) of pre-existing IP triggered by an infection was suspected, and the treatment with antibiotics and corticosteroid pulse therapy improved her general condition and chest radiological findings. Because some auto-antibodies associated with acute/subacute onset IP have recently become available in clinic, we examined those including anti-aminoacyl tRNA synthetase (ARS) antibodies, and found that she was positive for anti-PL-7 antibody. We diagnosed her anti-synthetase syndrome (ASS) without symptom of myositis, and her IP was considered to be ASS-related. The careful consideration is necessary to precisely diagnose and treat the patients with RA-associated interstitial lung diseases as the several etiologies may be overlapped in the same patient. J. Med. Invest. 65:147-150, February, 2018. (Keyword) Aged / Amino Acyl-tRNA Synthetases / Arthritis, Rheumatoid / Autoantibodies / female / Humans / Lung Diseases, Interstitial (Tokushima University Institutional Repository) ● Metadata: 111454 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.65.147 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29593187 ● CiNii @ National Institute of Informatics (CRID): 1390282679224622464 ● Summary page in Scopus @ Elsevier: 2-s2.0-85044475211 (Tokushima University Institutional Repository: 111454, DOI: 10.2152/jmi.65.147, PubMed: 29593187, CiNii: 1390282679224622464, Elsevier: Scopus)
21.	Hitoshi Nishijima, Tatsuya Kajimoto, Yoshiki Matsuoka, Yasuhiro Mouri, Junko Morimoto, Minoru Matsumoto, Hiroshi Kawano, Yasuhiko Nishioka, Hisanori Uehara, Keisuke Izumi, Koichi Tsuneyama, Il-mi Okazaki, Taku Okazaki, Kazuyoshi Hosomichi, Ayako Shiraki, Makoto Shibutani, Kunitoshi Mitsumori and Mitsuru Matsumoto : Paradoxical development of polymyositis-like autoimmunity through augmented expression of autoimmune regulator (AIRE)., Journal of Autoimmunity, Vol.86, 75-92, 2018. (Summary) Autoimmunity is prevented by the function of the autoimmune regulator [AIRE (Aire in mice)], which promotes the expression of a wide variety of tissue-restricted antigens (TRAs) from medullary thymic epithelial cells (mTECs) and from a subset of peripheral antigen-presenting cells (APCs). We examined the effect of additive expression of human AIRE (huAIRE) in a model of autoimmune diabetes in NOD mice. Unexpectedly, we observed that mice expressing augmented AIRE/Aire developed muscle-specific autoimmunity associated with incomplete maturation of mTECs together with impaired expression of Aire-dependent TRAs. This led to failure of deletion of autoreactive T cells together with dramatically reduced production of regulatory T cells in the thymus. In peripheral APCs, expression of costimulatory molecules was augmented. We suggest that levels of Aire expression need to be tightly controlled for maintenance of immunological tolerance. Our results also highlight the importance of coordinated action between central tolerance and peripheral tolerance under the common control of Aire. (Tokushima University Institutional Repository) ● Metadata: 112347 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jaut.2017.09.006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28931462 ● Search Scopus @ Elsevier (PMID): 28931462 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jaut.2017.09.006 (Tokushima University Institutional Repository: 112347, DOI: 10.1016/j.jaut.2017.09.006, PubMed: 28931462)
22.	Seidai Satou, Shinohara Shintaro, Hayashi Shinya, Morizumi Shun, Abe Shuichi, Okazaki Hiroyasu, Chen Yanjuan, Hisatsugu Goto, Yoshinori Aono, Hirohisa Ogawa, Koyama Kazuya, Nishimura Haruka, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara and Yasuhiko Nishioka : Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity., Respiratory Research, Vol.18, No.1, 172, 2017. (Summary) Nintedanib, a tyrosine kinase inhibitor that is specific for platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and vascular endothelial growth factor receptors (VEGFR), has recently been approved for idiopathic pulmonary fibrosis. Fibrocytes are bone marrow-derived progenitor cells that produce growth factors and contribute to fibrogenesis in the lungs. However, the effects of nintedanib on the functions of fibrocytes remain unclear. Human monocytes were isolated from the peripheral blood of healthy volunteers. The expression of growth factors and their receptors in fibrocytes was analyzed using ELISA and Western blotting. The effects of nintedanib on the ability of fibrocytes to stimulate lung fibroblasts were examined in terms of their proliferation. The direct effects of nintedanib on the differentiation and migration of fibrocytes were also assessed. We investigated whether nintedanib affected the accumulation of fibrocytes in mouse lungs treated with bleomycin. Human fibrocytes produced PDGF, FGF2, and VEGF-A. Nintedanib and specific inhibitors for each growth factor receptor significantly inhibited the proliferation of lung fibroblasts stimulated by the supernatant of fibrocytes. Nintedanib inhibited the migration and differentiation of fibrocytes induced by growth factors in vitro. The number of fibrocytes in the bleomycin-induced lung fibrosis model was reduced by the administration of nintedanib, and this was associated with anti-fibrotic effects. These results support the role of fibrocytes as producers of and responders to growth factors, and suggest that the anti-fibrotic effects of nintedanib are at least partly mediated by suppression of fibrocyte function. (Keyword) Animals / Cell Movement / Cells, Cultured / Dose-Response Relationship, Drug / Fibroblasts / Humans / Indoles / Male / Mice / Mice, Inbred C57BL / Pulmonary Fibrosis / Treatment Outcome / Vascular Endothelial Growth Factor A (Tokushima University Institutional Repository) ● Metadata: 114546 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12931-017-0654-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28915889 ● Summary page in Scopus @ Elsevier: 2-s2.0-85029541214 (Tokushima University Institutional Repository: 114546, DOI: 10.1186/s12931-017-0654-2, PubMed: 28915889, Elsevier: Scopus)
23.	Soji Kakiuchi, Masaki Hanibuchi, Toshifumi Tezuka, Atsuro Saijo, Kenji Otsuka, Satoshi Sakaguchi, Yuko Toyoda, Hisatsugu Goto, Hiroshi Kawano, Masahiko Azuma, Fumitaka Ogushi and Yasuhiko Nishioka : Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1., Respiratory Investigation, Vol.55, No.2, 145-152, 2016. (Summary) Although this was a small retrospective study, its findings showed that S-1 and etoposide may be relatively safe options for the treatment of patients with lung cancer and concomitant ILD. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.resinv.2016.10.008 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28274530 ● Search Scopus @ Elsevier (PMID): 28274530 ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2016.10.008 (DOI: 10.1016/j.resinv.2016.10.008, PubMed: 28274530)
24.	Yuko Toyoda, Masaki Hanibuchi, Jun Kishi, Hiroshi Kawano, Shun Morizumi, Seidai Satou, M Kondo, Terumi Takikura, Toshifumi Tezuka, Hisatsugu Goto and Yasuhiko Nishioka : Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease., The Journal of Medical Investigation : JMI, Vol.63, No.3,4, 294-299, 2016. (Summary) Acute exacerbation (AE) of interstitial lung disease is reported to be developed in not only idiopathic pulmonary fibrosis but also connective tissue disease-associated interstitial pneumonia (CTD-IP). As the significance of AE of CTD-IP has not been so widely recognized, its clinical feature is not fully elucidated. In the present study, we investigated the incidence, clinical features and outcome of AE of CTD-IP. We retrospectively reviewed admitted cases in our department with medical record from 2011 to 2015. Among 155 patients with CTD-IP, 10 (6.5%) cases developed AE (6 rheumatoid arthritis, 2 polymyositis/dermatomyositis, 1 systemic lupus erythematosus, 1 Sjögren syndrome), and one died of AE within 30 days. Median survival time after the onset of AE was 169 days in all 10 patients. The treatment with immunosuppressant just before AE onset might improve the prognosis of AE. The median survival time after the onset of AE was significantly longer in patients showing good response to corticosteroid compared with those with poor response to corticosteroid (805 days and 45 days, respectively) (p <0.05), suggesting that there are some cases in CTD-IP, showing the good response to corticosteroid even when AE was complicated. J. Med. Invest. 63: 294-299, August, 2016. (Tokushima University Institutional Repository) ● Metadata: 111197 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.63.294 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27644575 ● Summary page in Scopus @ Elsevier: 2-s2.0-84987881651 (Tokushima University Institutional Repository: 111197, DOI: 10.2152/jmi.63.294, PubMed: 27644575, Elsevier: Scopus)
25.	Hiroshi Kawano, Hitoshi Nishijima, Junko Morimoto, Fumiko Hirota, Ryoko Morita, Yasuhiro Mouri, Yasuhiko Nishioka and Mitsuru Matsumoto : Aire expression is inherent to most medullary thymic epithelial cells during their differentiation program., The Journal of Immunology, Vol.195, No.11, 5149-5158, 2015. (Summary) Aire in medullary thymic epithelial cells (mTECs) plays an important role in the establishment of self-tolerance. Because Aire+ mTECs appear to be a limited subset, they may constitute a unique lineage(s) among mTECs. An alternative possibility is that all mTECs are committed to express Aire in principle, but Aire expression by individual mTECs is conditional. To investigate this issue, we established a novel Aire reporter strain in which endogenous Aire is replaced by the human AIRE-GFP-Flag tag (Aire/hAGF-knockin) fusion gene. The hAGF reporter protein was produced and retained very efficiently within mTECs as authentic Aire nuclear dot protein. Remarkably, snapshot analysis revealed that mTECs expressing hAGF accounted for >95% of mature mTECs, suggesting that Aire expression does not represent a particular mTEC lineage(s). We confirmed this by generating Aire/diphtheria toxin receptor knockin mice in which long-term ablation of Aire+ mTECs by diphtheria toxin treatment resulted in the loss of most mature mTECs beyond the proportion of those apparently expressing Aire. These results suggest that Aire expression is inherent to all mTECs but may occur at particular stage(s) and/or cellular states during their differentiation, thus accounting for the broad impact of Aire on the promiscuous gene expression of mTECs. (Tokushima University Institutional Repository) ● Metadata: 109688 (Link to Publication Site) ● Publication site (DOI): 10.4049/jimmunol.1501000 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26503950 ● Search Scopus @ Elsevier (PMID): 26503950 ● Search Scopus @ Elsevier (DOI): 10.4049/jimmunol.1501000 (Tokushima University Institutional Repository: 109688, DOI: 10.4049/jimmunol.1501000, PubMed: 26503950)
26.	Hitoshi Nishijima, Satsuki Kitano, Hitoshi Miyachi, Junko Morimoto, Hiroshi Kawano, Fumiko Hirota, Ryoko Morita, Yasuhiro Mouri, Kiyoshi Masuda, Issei Imoto, Koichi Ikuta and Mitsuru Matsumoto : Ectopic Aire expression in the thymic cortex reveals inherent properties of Aire as a tolerogenic factor within the medulla., The Journal of Immunology, Vol.195, No.10, 4641-4649, 2015. (Summary) Cortical thymic epithelial cells (cTECs) and medullary thymic epithelial cells (mTECs) play essential roles in the positive and negative selection of developing thymocytes, respectively. Aire in mTECs plays an essential role in the latter process through expression of broad arrays of tissue-restricted Ags. To determine whether the location of Aire within the medulla is absolutely essential or whether Aire could also function within the cortex for establishment of self-tolerance, we used bacterial artificial chromosome technology to establish a semiknockin strain of NOD-background (β5t/Aire-transgenic) mice expressing Aire under control of the promoter of β5t, a thymoproteasome expressed exclusively in the cortex. Although Aire was expressed in cTECs as typical nuclear dot protein in β5t/Aire-Tg mice, cTECs expressing Aire ectopically did not confer transcriptional expression of either Aire-dependent or Aire-independent tissue-restricted Ag genes. We then crossed β5t/Aire-Tg mice with Aire-deficient NOD mice, generating a strain in which Aire expression was confined to cTECs. Despite the presence of Aire(+) cTECs, these mice succumbed to autoimmunity, as did Aire-deficient NOD mice. The thymic microenvironment harboring Aire(+) cTECs, within which many Aire-activated genes were present, also showed no obvious alteration of positive selection, suggesting that Aire's unique property of generating a self-tolerant T cell repertoire is functional only in mTECs. (Link to Publication Site) ● Publication site (DOI): 10.4049/jimmunol.1501026 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26453754 ● Summary page in Scopus @ Elsevier: 2-s2.0-84951861488 (DOI: 10.4049/jimmunol.1501026, PubMed: 26453754, Elsevier: Scopus)
27.	Hiroshi Kawano, Masaki Hanibuchi, Yoshijima Terumi, Yuko Toyoda, Jun Kishi, Toshifumi Tezuka and Yasuhiko Nishioka : A case of atypical Takayasu arteritis initially presenting with peripheral artery disease, Case Reports in Clinical Pathology, Vol.2, No.2, 34-40, 2015. (Link to Publication Site) ● Publication site (DOI): 10.5430/crcp.v2n2p34 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.5430/crcp.v2n2p34 (DOI: 10.5430/crcp.v2n2p34)
28.	Seidai Satou, Masaki Hanibuchi, Makoto Tobiume, Jun Kishi, Yuko Toyoda, Hiroshi Kawano, Mikiko Takahashi, Yuh Fukuda and Yasuhiko Nishioka : A case of IgG4-related interstitial lung disease showing usual interstitial pneumonia pattern: Unusual case for histological features with pathological proof, Case Reports in Clinical Pathology, Vol.2, No.1, 6-11, 2015. (Link to Publication Site) ● Publication site (DOI): 10.5430/crcp.v2n1p6 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.5430/crcp.v2n1p6 (DOI: 10.5430/crcp.v2n1p6)
29.	Seidai Satou, Hisatsugu Goto, 阿部秀一, 竹﨑彰夫, Hiroshi Kawano, Yoshinori Aono and Yasuhiko Nishioka : ヒトfibrocyte分化における遺伝子発現解析と分子標的治療薬による分化制御の検討, Respiratory Molecular Medicine, Vol.19, No.1, 135-139, 2015. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520854804901101056 (CiNii: 1520854804901101056)
30.	Yoshinori Aono, Masami Kishi, Yuki Yokota, Momoyo Azuma, Katsuhiro Kinoshita, Akio Takezaki, Seidai Sato, Hiroshi Kawano, Jun Kishi, Hisatsugu Goto, Hisanori Uehara, Keisuke Izumi and Yasuhiko Nishioka : Role of PDGF/PDGFR axis in the trafficking of circulating fibrocytes in pulmonary fibrosis, American Journal of Respiratory Cell and Molecular Biology, Vol.51, No.6, 793-801, 2014. (Summary) Circulating fibrocytes have been reported to migrate into the injured lungs, and contribute to fibrogenesis via CXCL12-CXCR4 axis. In contrast, we report that imatinib mesylate prevented bleomycin (BLM)-induced pulmonary fibrosis in mice by inhibiting platelet-derived growth factor receptor (PDGFR), even when it was administered only in the early phase. The goal of this study was to test the hypothesis that platelet-derived growth factor (PDGF) might directly contribute to the migration of fibrocytes to the injured lungs. PDGFR expression in fibrocytes was examined by flow cytometry and RT-PCR. The migration of fibrocytes was evaluated by using a chemotaxis assay for human fibrocytes isolated from peripheral blood. The numbers of fibrocytes triple-stained for CD45, collagen-1, and CXCR4 were also examined in lung digests of BLM-treated mice. PDGFR mRNA levels in fibrocytes isolated from patients with idiopathic pulmonary fibrosis were investigated by real-time PCR. Fibrocytes expressed both PDGFR-α and -β, and migrated in response to PDGFs. PDGFR inhibitors (imatinib, PDGFR-blocking antibodies) suppressed fibrocyte migration in vitro, and reduced the number of fibrocytes in the lungs of BLM-treated mice. PDGF-BB was a stronger chemoattractant than the other PDGFs in vitro, and anti-PDGFR-β-blocking antibody decreased the numbers of fibrocytes in the lungs compared with anti-PDGFR-α antibody in vivo. Marked expression of PDGFR-β was observed in fibrocytes from patients with idiopathic pulmonary fibrosis compared with healthy subjects. These results suggest that PDGF directly functions as a strong chemoattractant for fibrocytes. In particular, the PDGF-BB-PDGFR-β biological axis might play a critical role in fibrocyte migration into the fibrotic lungs. (Keyword) Animals / Benzamides / Case-Control Studies / Chemotaxis / Drug Evaluation, Preclinical / Female / Humans / Injections, Intraperitoneal / Mice, Inbred C57BL / Piperazines / Platelet-Derived Growth Factor / pulmonary fibrosis / Pyrimidines / Receptor, Platelet-Derived Growth Factor beta / Receptors, CXCR4 / signal transduction (Link to Publication Site) ● Publication site (DOI): 10.1165/rcmb.2013-0455OC (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24885373 ● Summary page in Scopus @ Elsevier: 2-s2.0-84918792291 (DOI: 10.1165/rcmb.2013-0455OC, PubMed: 24885373, Elsevier: Scopus)
31.	Yuko Toyoda, Sho Tabata, Jun Kishi, Takuya Kuramoto, Atsushi Mitsuhashi, Atsuro Saijo, Hiroshi Kawano, Hisatsugu Goto, Yoshinori Aono, Masaki Hanibuchi, Hideaki Horikawa, Toshihiro Nakajima, Tatsuhiko Furukawa, Saburo Sone, Shin-ichi Akiyama and Yasuhiko Nishioka : Thymidine Phosphorylase Regulates the Expression of CXCL10 in Rheumatoid Arthritis Fibroblast-like Synoviocytes, Arthritis & Rheumatology, Vol.66, No.3, 560-568, 2014. (Summary) Thymidine phosphorylase (TP) in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) is induced by tumor necrosis factor α (TNFα) and other cytokines that have been reported to be major inflammation mediators in RA. We previously demonstrated that TP plays an important role in angiogenesis and tumor growth, invasion, and metastasis. The aim of this study was to investigate whether the role of TP in the pathogenesis of RA is similar to its role in tumors. In FLS obtained from 2 patients with RA, the expression of TP, interferon-γ (IFNγ)-inducible protein 10 (CXCL10), and other cytokines was measured by quantitative real-time polymerase chain reaction, immunoblotting, and enzyme-linked immunosorbent assays. Microarray analysis was performed using FLS transfected with TYMP complementary DNA and treated with a TP inhibitor. The expression of TP in FLS was up-regulated by TNFα, interleukin-1β (IL-1β), IL-17, IFNγ, and lipopolysaccharide. Microarray analysis of FLS overexpressing TP identified CXCL10 as a thymidine phosphorylase-related gene. The expression of CXCL10 was induced by TNFα, and this induction was suppressed by TYMP small interfering RNA and TP inhibitor. Furthermore, the combination of TNFα and IFNγ synergistically augmented the expression of TP and CXCL10. TP-induced CXCL10 expression was suppressed by the antioxidant EUK-8. In the synovial tissue of patients with RA, TP levels were significantly correlated with CXCL10 expression. The combination of TNFα and IFNγ strongly induced the expression of thymidine phosphorylase in RA FLS. The induction of thymidine phosphorylase enhanced the expression of CXCL10, which may contribute to the Th1 phenotype and bone destruction observed in RA. (Keyword) Arthritis, Rheumatoid / Cells, Cultured / Chemokine CXCL10 / Cytokines / Humans / Interferon-gamma / Synovial Membrane / Thymidine Phosphorylase / Tumor Necrosis Factor-alpha (Tokushima University Institutional Repository) ● Metadata: 106062 (Link to Publication Site) ● Publication site (DOI): 10.1002/art.38263 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24574215 ● Summary page in Scopus @ Elsevier: 2-s2.0-84896289470 (Tokushima University Institutional Repository: 106062, DOI: 10.1002/art.38263, PubMed: 24574215, Elsevier: Scopus)
32.	矢野祖, Atsuro Saijo, 近藤真代, Hiroshi Kawano, Yuko Toyoda, Souji Kakiuchi, Jun Kishi, Masaki Hanibuchi, 古川貴大, Koji Fujita and Yasuhiko Nishioka : A case of neurosarcoidosis with radiculopathy, Shikoku Acta Medica, Vol.68, No.3,4, 153-158, 2012. (Summary) A52-year-old woman was referred to our hospital for further examination of thoracolumbarpain. As dysesthesia at Th4level was seen in neurological examination, thoracic radiculopathy ormyelopathy was suspected. Blood examination showed elevated level of serum ACE and lysozyme.Lymphadenopathy was evident in bilateral hila and mediastina with marked FDG and Galliumaccumulation in FDG-PET-CT and Gallium scintigraphy, respectively. The number of lymphocytesand the CD4/CD8ratio were increased in the BALF. Histological findings of specimens obtainedfrom the lung and the skin lesion revealed noncaseating epithelioid granuloma, which yielded thediagnosis of sarcoidosis. The cerebrospinal fluid examinations showed elevated level of cell counts,proteins and β2-microglobulin. Taken together, she was diagnosed as neurosarcoidosis with thoracicradiculopathy. Her symptoms were improved with oral administration of prednisolone, butthey were exacerbated when prednisolone dose was tapered to20mg/day. Combined therapy ofmethotrexate and prednisolone was initiated, thereafter her symptoms disappeared completely. (Keyword) neurosarcoidosis / radiculopathy / prednisolone / methotrexate (Tokushima University Institutional Repository) ● Metadata: 102837 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050845763842119680 (Tokushima University Institutional Repository: 102837, CiNii: 1050845763842119680)

Review, Commentary:

1.	Hiroshi Kawano and Yasuhiko Nishioka : グッドパスチャー症候群, The Journal of the Japan Medical Association, Vol.149, No.2, 244-246, Oct. 2020.
2.	Yuko Toyoda, Seidai Satou, Hiroshi Kawano and Yasuhiko Nishioka : Antirheumatic drugs and lung disease, Respiratory Medicine, Vol.36, No.6, 618-626, Dec. 2019. (Keyword) rheumatoid arthritis (RA) / drug-induced pneumonia / methotrexate (MTX) / biological drug / disease modifying antirheumatic drugs (DMARDs) (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523388080905010944 (CiNii: 1523388080905010944)
3.	Hiroshi Kawano and Yasuhiko Nishioka : 間質性肺炎・慢性閉塞性肺疾患, 薬局, Vol.70, No.5, 85-90, Apr. 2019.
4.	Shun Morizumi, Hiroshi Kawano, Yuko Toyoda, 小山壱也, Haruka Nishimura, Kohzoh Kagawa, Hisatsugu Goto and Yasuhiko Nishioka : ブレオマイシン肺線維症モデルにおける線維芽細胞増殖因子受容体阻害薬の抗線維化効果の検討, Respiratory Molecular Medicine, Vol.22, No.1, 96-98, Mar. 2018. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520573330524696832 (CiNii: 1520573330524696832)
5.	Hiroshi Kawano and Yasuhiko Nishioka : 膠原病における肺病変へのアプローチ, リウマチ科, Vol.55, No.4, 345-352, Apr. 2016.
6.	Yuko Toyoda, Hiroshi Kawano and Yasuhiko Nishioka : 間質性肺炎の免疫療法は有効か?, Respiratory Medicine, Vol.28, No.6, 451-455, 2015.

Proceeding of International Conference:

1.	Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Murakami Kojin, Yuya Yamashita, Danzan NandinErdene, Bando Hiroki, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : A novel senolytic drug, ARV-825, ameliorates experimental lung fibrosis, ERS International Congress 2023, Milano, Sep. 2023.
2.	Hiroki Bando, Seidai Satou, Hirohisa Ogawa, Kazuya Koyama, Murakami Kojin, Yuya Yamashita, Danzan Nandin-Erdene, Keiko Haji, Nobuhito Naito, Hiroshi Kawano and Yasuhiko Nishioka : Anamorelin, a ghrelin receptor agonist, inhibited the allergic airway inflammation in mice, ERS International Congress 2023, Milano, Sep. 2023.
3.	Murakami Kojin, Nishimura Haruka, Hiroshi Kawano, Danzan Nandin-Erdene, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kazuya Koyama, Seidai Satou and Yasuhiko Nishioka : Analysis of the Anti-fibrotic Potential of JAK Inhibitors in a Bleomycin-induced Pulmonary Fibrosis Model, ATS 2023, Washington, DC, May 2023.
4.	Kazuya Koyama, Seidai Satou, Hiroshi Kawano, Hiroshi Kawano, Atsushi Mitsuhashi, Murakami Kojin, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hirohisa Ogawa and Yasuhiko Nishioka : Evaluation of fibrocytes in silica-induced and bleomycin-induced pulmonary fibrosis model in mice by single cell RNA-seq analysis, APSR 2022, Seoul, Nov. 2022.
5.	Imakura Takeshi, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Murakami Kojin, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : Computational drug repositioning and wet-lab validation approach identifies polo-like kinase inhibitors as potential therapeutics for pulmonary fibrosis, ERS International Congress 2022, Barcelona, Sep. 2022.
6.	Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : A Novel Senolytic Agent, ARV-825, Ameliorates Bleomycin-InducedPulmonary Fibrosis in Mice, ATS 2022 International Conference, San Francisco, May 2022.
7.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : Computational Drug Repositioning Approach Identifies Polo-Like KinaseInhibitors as Potential Therapeutics for Pulmonary Fibrosis, ATS 2022 International Conference, San Francisco, May 2022.
8.	Kazuya Koyama, Hiroshi Kawano, Atsushi Mitsuhashi, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Seidai Satou, Hirohisa Ogawa and Yasuhiko Nishioka : Single Cell RNA-seq Analysis of Fibrocytes in Silica Induced Mouse Pulmonary Fibrosis Model, ATS 2022 International Conference, San Francisco, May 2022.
9.	Imakura Takeshi, Seidai Satou, Kazuya Koyama, Takahiro Niimura, Kohjin Murakami, Yuya Yamashita, Takahashi Naoki, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : Polo-like kinase inhibitors identified by computational repositioning attenuates bleomycin-induced pulmonary fibrosis in mice, APSR 2021, Kyoto and online, Nov. 2021.
10.	Kohjin Murakami, Takahashi Naoki, Seidai Satou, Imakura Takeshi, Yuya Yamashita, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Tanigawara Kazuaki, Toriumi Wataru and Yasuhiko Nishioka : Therapeutic effect of oligonucleotide therapeutics PK-7010 in mouse model of bleomycin-induced lung fibrosis, APSR 2021, Kyoto and online, Nov. 2021.
11.	Nobuhito Naito, Hiroshi Kawano, Imakura Takeshi, Yuya Yamashita, Kohjin Murakami, Kozo Kagawa, Kazuya Koyama, Seidai Satou, Hiroshi Nokihara, Inagaki Yutaka and Yasuhiko Nishioka : Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain, APSR 2021, Kyoto and online, Nov. 2021.
12.	Kozo Kagawa, Kazuya Koyama, Seidai Satou, Imakura Takeshi, Kohjin Murakami, Yuya Yamashita, Takahashi Naoki, Nobuhito Naito, Hiroshi Kawano and Yasuhiko Nishioka : A Lck-specific inhibitor, A-770041, attenuates pulmonary fibrosis via the suppression of TGF-b production in regulatory T cells, APSR 2021, Kyoto and online, Nov. 2021. (Link to Publication Site) ● Publication site (DOI): 10.1111/resp.14150_945 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1111/resp.14150_945 (DOI: 10.1111/resp.14150_945)
13.	Hiroshi Kawano, Nishimura Haruka, Imakura Takeshi, Yuya Yamashita, Kohjin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : Analysis of anti-fibrotic potential of JAK inhibitors in bleomycin-induced pulmonary fibrosis model, APSR 2021, Kyoto and online, Nov. 2021. (Link to Publication Site) ● Publication site (DOI): 10.1111/resp.14150_915 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1111/resp.14150_915 (DOI: 10.1111/resp.14150_915)
14.	Kozo Kagawa, Kazuya Koyama, Seidai Satou, Imakura Takeshi, Kohjin Murakami, Takahashi Naoki, Nobuhito Naito, Nishimura Haruka, Hiroshi Kawano and Yasuhiko Nishioka : Anti-fibrotic efficacy of Lck inhibitor via the suppression of TGF-β production in regulatory T cells, ERS International Congress 2021, WEB, Sep. 2021. (Link to Publication Site) ● Publication site (DOI): 10.1183/13993003.congress-2021.PA3285 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2021.PA3285 (DOI: 10.1183/13993003.congress-2021.PA3285)
15.	Takahashi Naoki, Seidai Satou, Imakura Takeshi, Kohjin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Tanigawara Kazuaki, Toriumi Wataru and Yasuhiko Nishioka : Oligonucleotide therapeutics PK-7010 in combination with nintedanib ameliorates bleomycin-induced pulmonary fibrosis in mice, ATS 2021, 米国(WEB), May 2021. (Link to Publication Site) ● Publication site (DOI): 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A4444 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A4444 (DOI: 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A4444)
16.	Kazuya Koyama, Hiroshi Kawano, Yuya Yamashita, Imakura Takeshi, Takahashi Naoki, Nobuhito Naito, Seidai Satou and Yasuhiko Nishioka : Clinical Features of the Acute Exacerbation of Rheumatoid Arthritis-Associated Interstitial Lung Disease, ATS 2021, 米国(WEB), May 2021.
17.	Takahashi Naoki, Seidai Satou, Imakura Takeshi, Murakami Kojin, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Tanigawara Kazuaki, Toriumi Wataru and Yasuhiko Nishioka : The novel oligonucleotide therapeutics PK-7010 for TGF-β1 ameliorates bleomycin-induced pulmonary fibrosis in micen, ERS International Congress 2020 Virtual, WEB, Sep. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1183/13993003.congress-2020.3373 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2020.3373 (DOI: 10.1183/13993003.congress-2020.3373)
18.	Seidai Satou, Yamamoto Takushi, Waki Kana, Morimoto Yuki, Imakura Takeshi, Murakami Kojin, Takahashi Naoki, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Koichi Tsuneyama and Yasuhiko Nishioka : Analysis of localization of nintedanib and cyclophosphamide in pulmonary fibrosisusing the iMScope TRIOS, ERS International Congress 2020 Virtual, WEB, Sep. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1183/13993003.congress-2020.3385 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2020.3385 (DOI: 10.1183/13993003.congress-2020.3385)
19.	Kozo Kagawa, Koyama Kazuya, Seidai Satou, Takahashi Naoki, Nishimura Haruka, Nobuhito Naito, Hiroshi Kawano, Yuko Toyoda and Yasuhiko Nishioka : Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice., ERS International Congress 2019, Madrid, Oct. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1183/13993003.congress-2019.PA5372 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2019.PA5372 (DOI: 10.1183/13993003.congress-2019.PA5372)
20.	Koyama Kazyua, Nobuhito Naito, Kozo Kagawa, Nishimura Haruka, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka : Acute Respiratory Failure in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease, ATS 2019 International Conference, Dallas, May 2019. (Link to Publication Site) ● Publication site (DOI): 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1445 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1445 (DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1445)
21.	Hiroshi Kawano, Koyama Kazuya, Nishimura Haruka, Yuko Toyoda, Kagawa Kozo, Seidai Satou, Naito Nobuhito, Hisatsugu Goto, Inagaki Yutaka and Yasuhiko Nishioka : Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain, ERS International Congress, Paris, Sep. 2018.
22.	Koyama Kazuya, Kagawa Kozo, Nishimura Haruka, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Hirohisa Ogawa, Hisanori Uehara and Yasuhiko Nishioka : Novel Multi-tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Pulmonary Fibrosis In Mice., ATS 2018 International Conference, San Diego, May 2018.
23.	Yuko Toyoda, Morizumi Shun, Seidai Satou, Okazaki Hiroyasu, Chen Yanjuan, Hisatsugu Goto, Hirohisa Ogawa, Nishimura Haruka, Koyama Kazuya, Hiroshi Kawano, Yoshinori Aono, Hisanori Uehara and Yasuhiko Nishioka : Role of Fibroblast Growth Factor/Fibroblast Growth Factor Receptor Signal in Bleomycin-Induced Pulmonary Fibrosis in Mice., ATS 2017 International Conference, Washington, D.C., May 2017.
24.	Seidai Satou, Hisatsugu Goto, Shun Morizumi, Hiroyasu Okazaki, Yajuan Chen, Hiroshi Kawano, Yuko Toyoda, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : Effect of blockade of fibroblast growth factor receptor signaling in experimental pulmonary fibrosis in mice, ATS 2016 International Conference, May 2016.
25.	Hiroshi Kawano, Hitoshi Nishijima, Junko Morimoto, Yasuhiro Mouri and Mitsuru Matsumoto : Aire expression is inherent to all medullary thymic epithelial cells during their differentiation program, The 4th European Congress of Immunology, Vienna, Austria, Sep. 2015.
26.	Katsuhiro Kinoshita, Yoshinori Aono, Hisatsugu Goto, Momoyo Azuma, Takezaki Akio, Yoshijima Terumi, Kishi Masami, Jun Kishi, Yuko Toyoda, Hiroshi Kawano, Abe Shuichi, Toshifumi Tezuka, Hisanori Uehara, Keisuke Izumi and Yasuhiko Nishioka : Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice., 18th Congress of the Asian Pacific Society of Respirology, Yokohama, Nov. 2013.

Proceeding of Domestic Conference:

1.	Noriko Bando, Hiroki Bandoh, Keiko Haji, 美馬正人, Asami Fukuya, Nobuhito Naito, Ryohiko Ozaki, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Satoshi Sakaguchi, Masaki Hanibuchi and Yasuhiko Nishioka : 当科における重症喘息に対する生物学的製剤の治療効果の検討, 第268回徳島医学会学術集会, Mar. 2024.
2.	山本浩生, Hiroki Bandoh, Keiko Haji, Yuya Yamashita, Nobuhito Naito, Seidai Satou, Hiroshi Kawano, Masaki Hanibuchi and Yasuhiko Nishioka : ステロイド抵抗性の気道病変に対してシクロホスファミドが著効した再発性多発軟骨炎の1例, 第129回日本内科学会四国地方会, Dec. 2023.
3.	Hiroshi Kawano, Yu Aoi, Katsuhiro Atagi, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 顕微鏡的多発血管炎の診断時にEBVの再活性化を呈し，リツキシマブにて寛解導入療法を行った1例, 第34回日本リウマチ学会中国・四国支部学術集会, Dec. 2023.
4.	Yu Aoi, Hiroshi Kawano, Katsuhiro Atagi, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 胸膜炎，間質性肺疾患を先行し，発熱性好中球減少症と肺病変の増悪で発症したSLEの1例, 第34回日本リウマチ学会中国・四国支部学術集会, Dec. 2023.
5.	Hiroki Bandoh, Seidai Satou, Kojin Murakami, Yuya Yamashita, Nobuhito Naitoh, Kazuya Koyama, Hiroshi Kawano, Hirohisa Ogawa and Yasuhiko Nishioka : グレリン受容体作動薬アナモレリンのアレルギー性気道炎症モデルマウスにおける検討, 第72回日本アレルギー学会学術大会, Oct. 2023.
6.	Seidai Satou, Hirohisa Ogawa, Kojin Murakami, Yuya Yamashita, Keiko Haji, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : BRD4 阻害剤 ARV825 の線維化関連遺伝子の発現抑制と老化細胞除去を介した抗線維化効果の検討, 第3回日本びまん性肺疾患研究会, Sep. 2023.
7.	Keiko Haji, Seidai Satou, Hirohisa Ogawa, Kojin Murakami, Yuya Yamashita, Kazuya Koyama, Hiroshi Kawano, 小林克利, 諸星俊郎 and Yasuhiko Nishioka : オートタキシン阻害作用を有する 2ccPA の肺線維症における有効性の検討, 第3回日本びまん性肺疾患研究会, Sep. 2023.
8.	寺澤翠, Hiroki Bandoh, Keiko Haji, 小路貴俊, Hiroto Yoneda, Seidai Satou, Hiroshi Kawano, Masaki Hanibuchi and Yasuhiko Nishioka : シクロスポリンが有効であった血清IL-18高値の重症成人発症スティル病の1例, 第128回日本内科学会四国地方会, Jul. 2023.
9.	Hiroki Bandoh, Seidai Satou, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Kazuya Koyama, Hiroshi Kawano, Hirohisa Ogawa and Yasuhiko Nishioka : グレリン受容体作動薬アナモレリンのアレルギー性気道炎症モデルマウスにおける検討, 第63回日本呼吸器学会学術講演会, Apr. 2023.
10.	Kojin Murakami, Seidai Satou, Yuya Yamashita, Keiko Haji, 坂東弘基, Nobuhito Naito, Kazuya Koyama, Hiroshi Kawano, 稲村典昭, 蓮見惠司 and Yasuhiko Nishioka : 新規可溶性エポキシヒドロラーゼ阻害薬SMTP-44Dの肺線維症に対する有効性の検討, 第63回日本呼吸器学会学術講演会, Apr. 2023.
11.	Hiroshi Kawano, 小路貴俊, Katsuhiro Atagi, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : リンパ球特異的チロシンキナーゼ阻害薬A-770041は制御性T細胞によるTGF-βs産生抑制を介して肺線維症を改善する, 第67回日本リウマチ学会総会・学術集会, Apr. 2023.
12.	新居香織, Keiko Haji, Yu Aoi, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Hiroshi Kawano, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 関節炎を呈したACTH 単独欠損症の1例, 第127回日本内科学会四国地方会, Dec. 2022.
13.	寺澤翠, Keiko Haji, 市原聖也, Yuya Yamashita, Asami Fukuya, Nobuhito Naito, Hiroto Yoneda, Kozo Kagawa, Hirokazu Ogino, Hiroshi Kawano, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 抗PD-L1抗体投与後に顕在化した抗ARS抗体陽性間質性肺炎の1例, 第67回日本呼吸器学会中国・四国地方会, Dec. 2022.
14.	小路貴俊, Nobuhito Naito, Hiroshi Kawano, Kojin Murakami, Yuya Yamashita, 美馬正人, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 両側声帯麻痺を呈した多発血管炎性肉芽腫症に伴う肥厚性硬膜炎の1例, 第33回日本リウマチ学会中国・四国支部学術集会, Dec. 2022.
15.	Katsuhiro Atagi, Hiroshi Kawano, 小路貴俊, Kojin Murakami, Yuya Yamashita, 美馬正人, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 劇症1型糖尿病と同時期に発症した両側特発性外眼筋炎の1例, 第33回日本リウマチ学会中国・四国支部学術集会, Dec. 2022.
16.	Nobuhito Naito, 西村春佳, Yuya Yamashita, Kojin Murakami, Keiko Haji, Kazuya Koyama, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Masaki Hanibuchi and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスを用いたJAK阻害薬の抗線維化効果についての検討, 第50回日本臨床免疫学会総会, Oct. 2022.
17.	Keiko Haji, Yohhei Yabuki, 美馬正人, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : MET阻害薬が著効したMET遺伝子 exon14 skipping 変異陽性肺扁平上皮癌の1例, 第126回日本内科学会四国地方会, Jun. 2022.
18.	高橋啓輝, Yohhei Yabuki, 市原聖也, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 重度の嚥下障害を合併した抗Ro52抗体陽性皮膚筋炎の1例, 第126回日本内科学会四国地方会, Jun. 2022.
19.	Hiroshi Kawano, Takeshi Imakura, Yuya Yamashita, Kojin Murakami, Nobuhito Naito, Seidai Satou and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスにおけるJAK阻害薬の抗線維化効果に関する検討, 第66回日本リウマチ学会総会・学術集会, Apr. 2022.
20.	Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : Antifibrotic and senolytic activity of novel BRD4 degrader ARV825 in experimental model of lung fibrosis, The 62nd Annual Meeting of the Japanese Respiratory Society, Apr. 2022.
21.	美馬正人, Seidai Satou, 原田紗希, 鈴江涼子, Yuya Yamashita, Ryohiko Ozaki, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 抗ARS抗体陽性間質性肺疾患の胸部画像所見の検討, 第62回日本呼吸器学会学術講演会, Apr. 2022.
22.	Kazuya Koyama, Atsushi Mitsuhashi, Takeshi Imakura, Kojin Murakami, Kozo Kagawa, Seidai Satou, Hiroshi Kawano, Hirohisa Ogawa and Yasuhiko Nishioka : シングルセル解析を用いた肺線維症マウスモデルにおけるfibrocyteの検討, 第62回日本呼吸器学会学術講演会, Apr. 2022.
23.	Hiroshi Kawano, Takeshi Imakura, Kojin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : レポーターマウスを用いた肺線維細胞の新規同定法, 第62回日本呼吸器学会学術講演会, Apr. 2022.
24.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : In silico解析により同定されたPLK阻害剤のブレオマイシン誘発肺線維症モデルマウスにおける効果の検討, 第62回日本呼吸器学会学術講演会, Apr. 2022.
25.	石田卓也, Hiroshi Kawano, Takeshi Imakura, Kohjin Murakami, Yuya Yamashita, 美馬正人, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 当院における膠原病関連間質性肺疾患に対するニンテダニブの使用経験, 第32回日本リウマチ学会中国・四国支部学術集会, Dec. 2021.
26.	市原聖也, Hiroshi Kawano, Takeshi Imakura, Kohjin Murakami, Yuya Yamashita, 美馬正人, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 再発性多発軟骨炎治療中の不明熱精査でUBA1遺伝子解析により診断したVEXAS症候群の1例, 第32回日本リウマチ学会中国・四国支部学術集会, Dec. 2021.
27.	市原聖也, YABUKI Yohhei, Kohjin Murakami, Kozo Kagawa, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 亜急性に進行し，蜂巣肺様の所見を呈した薬剤性肺障害の1例, 第125回日本内科学会四国地方会, Dec. 2021.
28.	石田卓也, YABUKI Yohhei, Kozo Kagawa, Yuya Yamashita, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 成人Still病との鑑別を要した家族性地中海熱非典型例の1例, 第125回日本内科学会四国地方会, Dec. 2021.
29.	村上尚哉, YABUKI Yohhei, Ryohiko Ozaki, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : Sitafloxacinが奏効した肺Mycobacterium abscessus subsp. massiliense 症の1例, 第72回日本結核・非結核性抗酸菌症学会中国四国支部会, Dec. 2021.
30.	高丸利加子, YABUKI Yohhei, 磯村祐太, Kozo Kagawa, Kazuya Koyama, Kenji Otsuka, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 自然退縮を認めた気管支原発唾液腺型腫瘍の1例, 第30回日本呼吸器内視鏡学会中国四国支部会, Dec. 2021.
31.	小川瑛, YABUKI Yohhei, 青井優, Kozo Kagawa, Kazuya Koyama, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 両側肺に多発する斑状影を呈した自己免疫性肺胞蛋白症の1例, 第65回日本呼吸器学会中国・四国地方会, Dec. 2021.
32.	原田祥子, YABUKI Yohhei, 美馬正人, Ryohiko Ozaki, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 非結核性抗酸菌症との鑑別を要し，amikacin + minocyclineが奏効した肺ノカルジア, 第65回日本呼吸器学会中国・四国地方会, Dec. 2021.
33.	Kazuya Koyama, Hiroshi Kawano and Yasuhiko Nishioka : 肺線維化におけるシングルセル解析, 第1回日本びまん性肺疾患研究会(基礎研究特別講演), Oct. 2021.
34.	Kohjin Murakami, Naoki Takahashi, Seidai Satou, Takeshi Imakura, Yuya Yamashita, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, 谷川原万顕, 鳥海亙 and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスにおける新規核酸医薬の有効性の検討, 第1回日本びまん性肺疾患研究会, Oct. 2021.
35.	Satoshi Sakaguchi, YABUKI Yohhei, Takeshi Imakura, Hiroto Yoneda, Kohjin Murakami, Kazuya Koyama, Kozo Kagawa, 小川瑛, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 索状の小葉間隔壁の肥厚を認め胸腔鏡下肺生検にて診断した間質性肺炎の1例, 第63回日本呼吸器学会中国・四国地方会, Aug. 2021.
36.	高丸利加子, Nobuhito Naito, 原田紗希, YAMASHITA Yuya, Ryohiko Ozaki, Naoki Takahashi, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 当科における全身性エリテマトーデスに対するベリムマブの使用経験, 第124回日本内科学会四国地方会, May 2021.
37.	石田卓也, Nobuhito Naito, Takeshi Imakura, Kozo Kagawa, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara, Tetsuji Takayama and Yasuhiko Nishioka : レンバチニブによる薬剤性肺障害の1例, 第124回日本内科学会四国地方会, May 2021.
38.	Yuya Yamashita, Takeshi Imakura, Naoki Takahashi, Nobuhito Naito, Seidai Satou, Hiroshi Kawano and Yasuhiko Nishioka : 関節リウマチに伴う間質性肺炎急性増悪の臨床的特徴 ∼特発性肺線維症急性増悪との比較検討∼, 第65回日本リウマチ学会総会・学術集会, Apr. 2021.
39.	Kohjin Murakami, Seidai Satou, Takeshi Imakura, 西村春佳, Naoki Takahashi, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Masahiko Azuma, Hiroshi Nokihara and Yasuhiko Nishioka : 抗線維化薬2剤を切り替えて使用した特発性肺線維症症例の後方視的検討, 第61回日本呼吸器学会学術講演会, Apr. 2021.
40.	西村春佳, Seidai Satou, Takeshi Imakura, Kohjin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスにおけるJAK阻害剤の効果に関する検討, 第61回日本呼吸器学会学術講演会, Apr. 2021.
41.	Naoki Takahashi, Seidai Satou, Takeshi Imakura, Kohjin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Hiroshi Nokihara, 谷川原万顕, 鳥海亙 and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスにおける核酸医薬PK-7010とnintedanibの併用効果の検討, 第61回日本呼吸器学会学術講演会, Apr. 2021.
42.	今倉健, Nobuhito Naito, Yuya Yamashita, 原田紗希, Kozo Kagawa, Hiroto Yoneda, Seidai Satou, Hiroshi Kawano, 長谷加容子, Hiroshi Nokihara and Yasuhiko Nishioka : 当科における成人発症スティル病症例の検討, 第262回徳島医学会学術集会, Mar. 2021.
43.	青井優, Nobuhito Naito, 今倉健, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : Atezolizumab投与後に著明な血小板減少症をきたした1例, 第262回徳島医学会学術集会, Mar. 2021.
44.	美馬正人, Nobuhito Naito, 原田紗希, 今倉健, 山下雄也, 髙橋直希, Seidai Satou, Hiroshi Kawano and Yasuhiko Nishioka : 当科における抗ARS抗体陽性症例の検討, 第31回日本リウマチ学会中国・四国支部学術集会, Dec. 2020.
45.	Yuya Yamashita, Nobuhito Naito, 原田紗希, 今倉健, 髙橋直希, Seidai Satou, Hiroshi Kawano and Yasuhiko Nishioka : ST合剤による無菌性髄膜炎を呈したシェーグレン症候群の一例, 第31回日本リウマチ学会中国・四国支部学術集会, Dec. 2020.
46.	原田紗希, Nobuhito Naito, 岡本悠里, Kozo Kagawa, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 不明熱の精査でMEFV遺伝子解析により診断した家族性地中海熱の1例, 第123回日本内科学会四国地方会, Nov. 2020.
47.	Akane Abe, Nobuhito Naito, Kenji Otsuka, Yukikiyo Kawakami, Shiroh Fujii, Seiji Iwamoto, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 非小細胞肺癌に合併した後天性血友病Aの1例, 第123回日本内科学会四国地方会, Nov. 2020.
48.	Hiroto Yoneda, Nobuhito Naito, Hiroyuki Kozai, Kenji Otsuka, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara, Masahiko Azuma and Yasuhiko Nishioka : 当科における悪性胸膜中皮腫に対するnivolumab投与症例の検討, 第123回日本内科学会四国地方会, Nov. 2020.
49.	折野逸人, Nobuhito Naito, 内藤仁美, 髙橋直希, Hironori Tanaka, Seidai Satou, Hiroshi Kawano, Hisanori Uehara, Hiroshi Nokihara, Tetsuji Takayama and Yasuhiko Nishioka : 肝肺症候群に進展したサルコイドーシスの1例, 第64回日本呼吸器学会中国・四国地方会, Nov. 2020.
50.	磯村祐太, Nobuhito Naito, 山下雄也, Asami Fukuya, Kazuya Koyama, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 当科における胸水貯留を呈した膠原病および類縁疾患症例の検討, 第64回日本呼吸器学会中国・四国地方会, Nov. 2020.
51.	梶本達也, Nobuhito Naito, 内藤仁美, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara, Masahiko Azuma and Yasuhiko Nishioka : 全身性強皮症に伴う間質性肺炎の増悪との鑑別を要した鳥関連過敏性肺炎の1例, 第29回日本呼吸器内視鏡学会中国四国支部会, Nov. 2020.
52.	國重道大, Nobuhito Naito, 原田紗季, 山下雄也, 高橋直希, 美馬正人, Hiroyuki Kozai, Seidai Satou, Hiroshi Kawano, Toshihiko Nishisho, Daisuke Hamada, Hiroshi Nokihara, Tetsuya Matsuura, Koichi Sairyo and Yasuhiko Nishioka : 当科における骨・関節病変を呈した非結核性抗酸菌症の検討, 第71回日本結核・非結核性抗酸菌症学会中国四国支部会, Nov. 2020.
53.	Hiroshi Kawano, Yuya Yamashita, Nobuhito Naito, Seidai Satou, Muneyuki Kadota, Takayuki Ise, Shusuke Yagi, Masataka Sata, Hiroshi Nokihara and Yasuhiko Nishioka : 高安動脈炎による難治性皮膚潰瘍に対してべペルミノゲンペルプラスミド(ヒト肝細胞増殖因子プラスミドベクター)投与が奏効した1例, 第48回日本臨床免疫学会総会, Oct. 2020.
54.	髙橋直希, Seidai Satou, Kazuya Koyama, Kozo Kagawa, Nobuhito Naito, 今倉健, Yuko Toyoda, Hiroshi Kawano, 谷川原万顕, 鳥海亙 and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスにおける核酸医薬PK-7010の抗線維化効果の検討, 第60回日本呼吸器学会学術講演会, Sep. 2020.
55.	Kozo Kagawa, Kazuya Koyama, Seidai Satou, Naoki Takahashi, 西村春佳, Hiroshi Kawano, Yuko Toyoda, Tsutomu Shinohara and Yasuhiko Nishioka : ブレオマイシン肺線維症マウスモデルにおけるLck阻害の抗線維化効果, 第60回日本呼吸器学会学術講演会, Sep. 2020.
56.	Yasuhiko Nishioka, Kazuya Koyama, Atsushi Mitsuhashi, Afroj Tania and Hiroshi Kawano : 肺線維症モデルにおけるscRNA-Seqを用いた線維細胞の解析, 第60回日本呼吸器学会学術講演会(シンポジウム), Sep. 2020.
57.	Hiroshi Kawano, Nobuhito Naito, 安宅克博, 今倉健, Yuya Yamashita, 高橋直希, Mayo Kondou, Seidai Satou, Yuko Toyoda and Yasuhiko Nishioka : 当院における進行性線維化を伴う膠原病関連間質性肺疾患の検討, 第64回日本リウマチ学会総会・学術集会, Aug. 2020.
58.	Seidai Satou, Kohjin Murakami, Yuko Toyoda, Kazuya Koyama, 西村春佳, Kozo Kagawa, 髙橋直希, Hiroshi Kawano, Masahiko Azuma and Yasuhiko Nishioka : 2剤の抗線維化薬を使用した特発性肺線維症症例の検討, 第117回日本内科学会講演会, Aug. 2020.
59.	青井優, Kozo Kagawa, Nobuhito Naito, Seidai Satou, Hiroshi Kawano, Jinsei Miyoshi, Tomomi Matsuura, Hideya Kashihara, Kouzou Yoshikawa, Yuko Toyoda, Yoshimi Bando, Hiroshi Nokihara, Tetsuji Takayama, Mitsuo Shimada and Yasuhiko Nishioka : 好酸球性多発血管炎性肉芽腫症の治療中に回腸出血をきたし，血管炎との鑑別が困難であったCMV腸炎の1例, 第260回徳島医学会学術集会, Feb. 2020.
60.	安宅克博, Hiroshi Kawano, Takeshi Imakura, Nobuhito Naito, Mayo Kondou, Seidai Satou, Yuko Toyoda and Yasuhiko Nishioka : 蛋白濾出性胃腸症，クリオグロブリン血症を伴ったMCTDの1例, 第30回日本リウマチ学会中国・四国支部学術集会, Dec. 2019.
61.	Nobuhito Naito, Hiroshi Kawano, Takeshi Imakura, Mayo Kondou, Seidai Satou, Yuko Toyoda and Yasuhiko Nishioka : 当科におけるANCA陽性間質性肺炎症例の検討, 第30回日本リウマチ学会中国・四国支部学術集会, Dec. 2019.
62.	石田卓也, Kozo Kagawa, Hiroto Yoneda, Kenji Nishimura, 山本遥平, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 顕微鏡的多発血管炎の治療中に重症筋無力症クリーゼを発症した1例, 第121回日本内科学会四国地方会, Dec. 2019.
63.	石田卓也, Kozo Kagawa, Hiroto Yoneda, 坂東紀子, Nobuhito Naito, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Kenji Nishimura, 山本遥平, Yuko Toyoda, Hiroshi Nokihara and Yasuhiko Nishioka : 顕微鏡的多発血管炎の治療中に重症筋無力症クリーゼを発症した1例, 第259回徳島医学会学術集会, Aug. 2019.
64.	Kozo Kagawa, 小山壱也, Seidai Satou, Naoki Takahashi, 西村春佳, Nobuhito Naito, Hiroshi Kawano, Yuko Toyoda and Yasuhiko Nishioka : ブレオマイシン肺線維症マウスモデルにおけるLck阻害の抗線維化効果, 第61回日本呼吸器学会中国・四国地方会, Jul. 2019.
65.	内藤仁美, Kozo Kagawa, Mayo Kondou, Seidai Satou, Nobuhito Naito, Hiroshi Kawano, Yuko Toyoda, Masahiko Azuma, Hiroshi Nokihara and Yasuhiko Nishioka : 関節リウマチで治療中に抗MDA5抗体陽性をみとめ，無筋症性皮膚筋炎と診断された間質性肺炎の2例, 第61回日本呼吸器学会中国・四国地方会, Jul. 2019.
66.	Asami Fukuya, Yuko Toyoda, Hirokazu Ogino, Hiroshi Kawano, Hisatsugu Goto, Hiroshi Nokihara, Masahiko Azuma and Yasuhiko Nishioka : Stevens-Johnson症候群後に合併した閉塞性細気管支炎にステロイドおよびタクロリムスが有効であった1例, 第6回日本呼吸ケア・リハビリテーション学会中国・四国支部学術集会, Jun. 2019.
67.	髙橋直希, Nobuhito Naito, Mayo Kondou, Hirokazu Ogino, Hiroshi Kawano, Yuko Toyoda, Hirokazu Miki, Masahiko Azuma, Hiroshi Nokihara and Yasuhiko Nishioka : 治療抵抗性のSLEに伴う赤芽球癆にシクロホスファミドパルス療法が著効した1例, 第120回日本内科学会四国地方会, May 2019.
68.	Nobuhito Naito, Hiroshi Kawano, Mayo Kondou, Hirokazu Ogino, Seidai Satou, Yuko Toyoda, Hisatsugu Goto and Yasuhiko Nishioka : 間質性肺炎合併関節リウマチに対するJAK阻害薬の使用経験, 第63回日本リウマチ学会総会・学術集会, Apr. 2019.
69.	Hiroyasu Okazaki, Seidai Satou, Shun Morizumi, 小山壱也, Hirohisa Ogawa, Kozo Kagawa, 西村春佳, Chen Yajuan, Yoshinori Aono, Shuichi Abe, Momoyo Azuma, Hisatsugu Goto, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara, 小路弘行 and Yasuhiko Nishioka : ブレオマイシン肺線維症マウスモデルにおけるWnt/B-カテニン/CBPシグナル阻害薬PRI-724による抗線維化効果の検討, 第59回日本呼吸器学会学術講演会, Apr. 2019.
70.	Hiroshi Nokihara, Masaki Hanibuchi, Souji Kakiuchi, Atagi Shinji, Ogushi Fumitaka, Shimizu Eiji, Haku Takashi, Yuko Toyoda, Masahiko Azuma, Mayo Kondou, Hiroshi Kawano, Kenji Otsuka, Satoshi Sakaguchi, Hisatsugu Goto and Yasuhiko Nishioka : A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced NSCLC patients with interstitial lung disease, The 59th Annual Meeting of the Japanese Respiratory Society, Apr. 2019.
71.	小山壱也, Nobuhito Naito, Kozo Kagawa, 西村春佳, Seidai Satou, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka : 関節リウマチ合併間質性肺炎患者の急性呼吸不全の臨床的検討, 第59回日本呼吸器学会学術講演会, Apr. 2019.
72.	小山壱也, Nobuhito Naito, Kozo Kagawa, Mayo Kondou, 西村春佳, Seidai Satou, Hiroshi Kawano, Yuko Toyoda, Masahiko Azuma, Hisatsugu Goto and Yasuhiko Nishioka : マウス肺線維症モデルにおける新規multi-tyrosine kinase inhibitor TAS-115の抗線維化効果の検討, 第258回徳島医学会学術集会, Feb. 2019.
73.	坂東紀子, Mayo Kondou, Hiroshi Kawano, Yasuteru Fujino, Toshiya Okahisa, Yuko Toyoda, Hiroshi Nokihara, Masahiko Azuma, Hisatsugu Goto, Tetsuji Takayama and Yasuhiko Nishioka : 潰瘍性大腸炎加療中に発症し，治療に難渋したニューモシスチス肺炎の一例, 第60回日本呼吸器学会中国・四国地方会, Dec. 2018.
74.	原田紗希, Mayo Kondou, 西村春佳, Nobuhito Naito, Hiroshi Kawano, Yusuke Osaki, Yoshimi Bando, Naoki Takahashi, Kozo Kagawa, Yasuhiko Nishioka, Hirokazu Ogino, Makoto Tobiume, Atsuro Saijo, Hiroshi Nokihara, Yuko Toyoda, Masahiko Azuma, Hisatsugu Goto, Hisanori Uehara and Yasuhiko Nishioka : 傍腫瘍性神経症候群を合併した小細胞肺癌の一例, 第60回日本呼吸器学会中国・四国地方会, Dec. 2018.
75.	Hiroki Bandoh, Mayo Kondou, Ryo Miyagi, Hirokazu Ogino, Makoto Tobiume, Takeshi Oya, Hirohisa Ogawa, Hiroshi Kawano, Yuko Toyoda, Hiroshi Nokihara, Masahiko Azuma, Hisatsugu Goto, Koichi Sairyo and Yasuhiko Nishioka : エイの刺創後に発症した皮膚Mycobacterium massiliense症の一例, 第69回日本結核病学会中国四国支部会, Dec. 2018.
76.	Seidai Satou, Yuko Toyoda, Nobuhito Naitoh, Hiroto Yoneda, Kohzoh Kagawa, Haruka Nishimura, Mayo Kondou, 小山壱也, Hiroshi Kawano, Hisatsugu Goto and Yasuhiko Nishioka : 気管支肺胞洗浄液中fibrocyteにおけるmiR-21発現の疾患別差異に関する検討, 第27回日本呼吸器内視鏡学会中国四国支部会, Dec. 2018.
77.	宮本憲哉, Mayo Kondou, Nobuhito Naitoh, Hiroki Yamazaki, Yuko Toyoda, Hirokazu Ogino, Hiroshi Kawano, Hisatsugu Goto, Ryuji Kaji and Yasuhiko Nishioka : 免疫介在性壊死性ミオパチーの1例, 第119回日本内科学会四国地方会, Dec. 2018.
78.	Yuya Yamashita, Hiroshi Kawano, Takeshi Imakura, Nobuhito Naito, Mayo Kondou, Hirokazu Ogino, Seidai Satou, Yuko Toyoda, 後東久嗣 and Yasuhiko Nishioka : TAFRO症候群の1例, 第29回日本リウマチ学会中国・四国支部学術集会, Dec. 2018.
79.	Nobuhito Naitoh, Hiroshi Kawano, Mayo Kondou, Hirokazu Ogino, Seidai Satou, Yuko Toyoda, Hisatsugu Goto and Yasuhiko Nishioka : EBウイルス再活性化を反復した高疾患活動性関節リウマチに対してアバタセプトが有効であった1例, 第29回日本リウマチ学会中国・四国支部学術集会, Nov. 2018.
80.	Hiroto Yoneda, Hirokazu Ogino, Yuko Toyoda, Hiroshi Kawano, Kenji Ohtsuka, Atsuro Saijo, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : 高齢肺癌患者の若年者と比較した臨床的特徴, 第56回日本癌治療学会学術集会, Oct. 2018.
81.	Katsuya Morito, Ryota Shimizu, Naoko Takahashi, 下澤伸行, Momoyo Azuma, Hiroshi Kawano, Yasuhiko Nishioka, Tatsuya Fukuta, Kentaro Kogure and Tamotsu Tanaka : ヒト血漿中セラミド及びセラミド1-リン酸の分子種組成と細胞への取り込み, 第91回日本生化学会大会, Sep. 2018.
82.	森あずさ, Nobuhito Naitoh, 山﨑博輝, 林理恵, 坂東紀子, 原田沙希, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Ryuji Kaji, Yoshiaki Kubo and Yasuhiko Nishioka : 免疫介在性壊死性ミオパチーの1例, 第257回徳島医学会学術集会, Aug. 2018.
83.	國重道大, Hiroto Yoneda, Hiroshi Kawano, Atsuro Saijo, Makoto Tobiume, Mayo Kondou, Hiroki Bandoh, Hirohisa Ogawa, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : 腸型肺腺癌の1例, 第57回日本肺癌学会中国・四国支部学術集会, Jul. 2018.
84.	坂東紀子, Yuko Toyoda, Hiroshi Kawano, Seidai Satou, 小山壱也, 西村春佳, Kozo Kagawa, Nobuhito Naitoh, Masahiko Azuma and Yasuhiko Nishioka : 当科で経験した抗MDA5抗体陽性皮膚筋炎合併間質性肺炎の臨床像の検討, 第59回日本呼吸器学会中国・四国地方会, Jul. 2018.
85.	Nobuhito Naitoh, 森田優, Kozo Kagawa, Mayo Kondou, 西村春佳, Hiroshi Kawano, Yuko Toyoda, Jun Kishi, Hisatsugu Goto and Yasuhiko Nishioka : Tocilizumab が有効であった重症成人発症スティル病の1例, 第118回日本内科学会四国地方会, Jun. 2018.
86.	小山壱也, Yuko Toyoda, Haruka Nishimura, Kohzoh Kagawa, Shun Morizumi, Hiroshi Kawano, Hisatsugu Goto and Yasuhiko Nishioka : マウス肺線維症モデルにおけるmulti-tyrosine kinase inhibitor TAS-115の抗線維化効果の検討．, 第58回日本呼吸器学会学術講演会., Apr. 2018.
87.	Haruka Nishimura, Shun Morizumi, Yuko Toyoda, 鈴江涼子, 小山壱也, Kohzoh Kagawa, Nobuhito Naitoh, Hiroshi Kawano, Hisatsugu Goto and Yasuhiko Nishioka : 当院における特発性肺線維症に対するNintedanibの治療症例の検討．, 第58回日本呼吸器学会学術講演会, Apr. 2018.
88.	Nobuhito Naitoh, Hiroshi Kawano, 山下雄也, Mayo Kondoh, Hirokazu Ogino, Yuko Toyoda, Jun Kishi, Hisatsugu Goto and Yasuhiko Nishioka : アザチオプリン併用療法が有効であった間質性肺炎合併抗MDA5抗体陽性皮膚筋炎の3例．, 第62回日本リウマチ学会総会・学術集会, Apr. 2018.
89.	Nobuhito Naitoh, 森田優, Kenji Ohtsuka, Hiroshi Kawano, Yuko Toyoda, Jun Kishi, Hisatsugu Goto and Yasuhiko Nishioka : Tocilizumabが有効であった重症成人発症スティル病の1例．, 第256回徳島医学会学術集会, Feb. 2018.
90.	辻本賀美, Nobuhito Naitoh, Mayo Kondoh, Hiroyuki Kozai, Hiroshi Kawano, Kenji Ohtsuka, Hisatsugu Goto, Jun Kishi, Masahiko Azuma and Yasuhiko Nishioka : 多発単神経炎を合併した好酸球性多発血管炎性肉芽腫症(EGPA)において免疫グロブリン大量療法(IVIG)が有効であった3例, 第117回日本内科学会四国地方会, Dec. 2017.
91.	山下雄也, Hiroshi Kawano, Jun Kishi, Nobuhito Naitoh, Hirokazu Ogino, Mayo Kondoh, Shun Morizumi, Yuko Toyoda, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka : 全身性強皮症を背景にposterior reversible encephalopathy syndromeを発症した一例, 第28回日本リウマチ学会中国・四国支部学術集会, Nov. 2017.
92.	今倉健, Nobuhito Naitoh, 山下雄也, Hirokazu Ogino, Jun Kishi, Hiroshi Kawano, Mayo Kondoh, Shun Morizumi, Yuko Toyoda, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka : ループス心筋炎の2例, 第28回日本リウマチ学会中国・四国支部学術集会, Nov. 2017.
93.	Hiroshi Kawano, Mitsuru Matsumoto and Yasuhiko Nishioka : ほぼすべての胸腺髄質上皮細胞が成熟過程でAireを発現する機能を備えている, 第28回日本リウマチ学会中国・四国支部学術集会, Nov. 2017.
94.	Hirokazu Ogino, Yuko Toyoda, Hiroshi Kawano, Jun Kishi, Mayo Kondoh, Shun Morizumi, 山下雄也, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka : 当院における肺病変合併全身性エリテマトーデス症例の臨床的検討, 第28回日本リウマチ学会中国・四国支部学術集会, Nov. 2017.
95.	鈴江涼子, Haruka Nishimura, Hirokazu Ogino, Kenji Ohtsuka, Makoto Tobiume, Hiroshi Kawano, Asami Fukuya, 山下雄也, Hisatsugu Goto and Yasuhiko Nishioka : 心タンポナーデをきたした結核性心膜炎の1例, 第68回日本結核病学会中国四国支部会, Oct. 2017.
96.	鈴江涼子, Shun Morizumi, Kenji Ootsuka, Yuko Toyoda, Hiroshi Kawano, 小山壱也, Hiroyuki Kozai, Haruka Nishimura, Hisatsugu Goto and Yasuhiko Nishioka : 特発性肺線維症に対するnintedanibの使用経験, 第57回日本呼吸器学会中国・四国地方会, Jul. 2017.
97.	Haruka Nishimura, Toshifumi Tezuka, Atsuro Saijo, Hiroshi Kawano, Hisatsugu Goto, Jun Kishi, Hiroshi Nokihara, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 肺扁平上皮癌治療後の空洞病変に認めた肺アスペルギルス症の1例, 第116回日本内科学会四国地方会, May 2017.
98.	Mayo Kondoh, Toshifumi Tezuka, Hiroshi Kawano, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi, Masahiko Azuma, 土師正太郎, Ryuji Kaji and Yasuhiko Nishioka : 小脳浮腫および水頭症を認め開頭減圧術を要したNPSLEの1例, 第116回日本内科学会四国地方会, May 2017.
99.	Yuko Toyoda, Jun Kishi, Hiroshi Kawano, Shun Morizumi, 小山壱也, Haruka Nishimura, Kohzoh Kagawa, Toshifumi Tezuka, Hisatsugu Goto, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 当院における全身性エリテマトーデス合併間質性肺炎の臨床的検討, 第57回日本呼吸器学会学術講演会, Apr. 2017.
100.	Shun Morizumi, Seidai Satou, Hirokazu Ogino, Koyama Kazuya, Haruka Nishimura, Yuko Toyoda, Hiroshi Kawano and Yasuhiko Nishioka : Inhibition of pan-fibroblast growth factor receptor signaling in bleomycin-induced pulmonary fibrosis in mice, The 57th Annual Meeting of the Japanese Respiratory Society, Apr. 2017.
101.	Hiroshi Kawano, Yuko Toyoda, Jun Kishi, Shun Morizumi, Mayo Kondoh, 山下雄也, Toshifumi Tezuka, Hisatsugu Goto, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 当院における間質性肺炎合併全身性エリテマトーデス症例の臨床的検討, 第61回日本リウマチ学会総会・学術集会, Apr. 2017.
102.	Takuya Takashima, Toshifumi Tezuka, 近藤真代, Makoto Tobiume, Hiroshi Kawano, Hisatsugu Goto, Jun Kishi, Masahiko Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : Exon19とexon21の遺伝子変異を同時に認めた肺腺癌の1例, 第56回日本呼吸器学会中国・四国地方会, Dec. 2016.
103.	菊地高史, Toshifumi Tezuka, 近藤真代, Hirokazu Ogino, Hiroshi Kawano, Hisatsugu Goto, Jun Kishi, Masahiko Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : Stevens-Johnson 症候群後に発症した閉塞性細気管支炎にステロイドおよびタクロリムスが有効であった1例, 第56回日本呼吸器学会中国・四国地方会.岡山.2016年12月23, Dec. 2016.
104.	杉峯優人, Toshifumi Tezuka, 香川耕造, 米田浩人, 大塚憲司, Hiroshi Kawano, Hisatsugu Goto, Jun Kishi, Masahiko Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : EBUS-TBNA後に縦隔炎を発症した縦隔原発セミノーマの1例, 第25回日本呼吸器内視鏡学会中国四国支部会, Dec. 2016.
105.	Tomoyo Hara, Toshifumi Tezuka, 近藤真代, Hiroshi Kawano, Hisatsugu Goto, Jun Kishi, Masahiko Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : EBによる末梢神経障害を呈した結核性胸膜炎の1例, 第67回日本結核病学会中国四国支部会, Dec. 2016.
106.	Yuko Toyoda, 山下雄也, Shun Morizumi, Mayo Kondoh, Hirokazu Ogino, Hiroshi Kawano, Toshifumi Tezuka, Jun Kishi, Hisatsugu Goto, Masaki Hanibuchi, Masaki Hanibuchi and Yasuhiko Nishioka : 当院における膠原病関連間質性肺炎の急性憎悪の臨床的検討, 第27回日本リウマチ学会中国・四国支部学術集会, Dec. 2016.
107.	Hirokazu Ogino, Jun Kishi, Hiroshi Kawano, Toshifumi Tezuka, Yuko Toyoda, Hisatsugu Goto, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 関節リウマチの薬物療法における栄養状態の変化の検討, 第27回日本リウマチ学会中国・四国支部学術集会, Dec. 2016.
108.	山下雄也, Yuko Toyoda, Hirokazu Ogino, Hiroshi Kawano, Toshifumi Tezuka, Jun Kishi, Hisatsugu Goto, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 当院におけるループス腎炎に対するIVCYとMMFの治療経験, 第27回日本リウマチ学会中国・四国支部学術集会, Dec. 2016.
109.	田中こころ, Hirokazu Ogino, Jun-ya Miyata, 山下雄也, Shun Morizumi, Mayo Kondoh, Hiroshi Kawano, Toshifumi Tezuka, Yuko Toyoda, Jun Kishi, Hisatsugu Goto, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 15年前より認める慢性腎機能障害に対してステロイド加療が奏功した腎サルコイドーシスの1例, 第27回日本リウマチ学会中国・四国支部学術集会, Dec. 2016.
110.	Hiroto Yoneda, Toshifumi Tezuka, 山下雄也, Atsuro Saijo, Hiroshi Kawano, Hisatsugu Goto, Jun Kishi, Masahiko Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : 多発性胃十二指腸潰瘍を伴ったMTX関連リンパ増殖性疾患の1例, 第115回日本内科学会四国地方会, Nov. 2016.
111.	香西博之, Toshifumi Tezuka, 山下雄也, Atsuro Saijo, Hiroshi Kawano, Hisatsugu Goto, Jun Kishi, Masahiko Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : Gefitinib投与中にAchromobacter Xylosoxidansによる菌血症を発症した肺腺癌の1例, 第115回日本内科学会四国地方会, Nov. 2016.
112.	森住俊, Seidai Satou, Hirokazu Ogino, Hiroshi Kawano, Satoshi Sakaguchi, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 当院におけるニンテダニブの特発性肺線維症に対する使用経験, 第114回日本内科学会四国地方会, May 2016.
113.	Hiroshi Kawano, Mayo Kondoh, Atsuro Saijo, Yuko Toyoda, Jun Kishi and Yasuhiko Nishioka : 当院における膠原病に合併した肺癌の検討, 第60回日本リウマチ学会総会・学術集会, Apr. 2016.
114.	Yuko Toyoda, Seidai Satou, Jun Kishi, Hiroshi Kawano, 森住俊, 岸昌美, Toshifumi Tezuka, Satoshi Sakaguchi, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 当院における膠原病関連間質性肺炎の急性増悪に関する臨床的検討, 第56回日本呼吸器学会学術講演会, Apr. 2016.
115.	Toshifumi Tezuka, Hirohisa Ogawa, Mayo Kondoh, Masahiko Azuma, Yuko Toyoda, Seidai Satou, Hiroyasu Okazaki, Hiroshi Kawano, Jun Kishi, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : RAS阻害剤 (XRP44X) を用いた喘息モデルマウスにおける検討, 第56回日本呼吸器学会学術講演会, Apr. 2016.
116.	曽我部洋平, Seidai Satou, Atsuro Saijo, Mayuri Nakano, Hiroshi Kawano, Satoshi Sakaguchi, Yuko Toyoda, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : 癌性髄膜炎に対しアファチニブが奏効した2例, 第54回日本呼吸器学会中国・四国地方会, Dec. 2015.
117.	山下雄也, Hirokazu Ogino, Jun Kishi, Yuko Toyoda, Shun Morizumi, Mayo Kondoh, Terumi Takikura, Seidai Satou, Hiroshi Kawano, Toshifumi Tezuka, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 強膜炎，ネフローゼ症候群および僧房弁腱索断裂による重症僧房弁閉鎖不全症を呈した全身性エリテマトーデスの1例, 第26回日本リウマチ学会中国・四国支部学術集会, Dec. 2015.
118.	Junko Morimoto, Yumiko Nishikawa, Hiroshi Kawano, Yasuhiro Mouri, Hitoshi Nishijima and Mitsuru Matsumoto : A novel Aire-dependent subset of medullary thymic epithelial cells that express Ly6 family protein, 第44回日本免疫学会学術集会, Nov. 2015.
119.	Hitoshi Nishijima, Yasuhiro Mouri, Junko Morimoto, Hiroshi Kawano and Mitsuru Matsumoto : Paradoxical development of polymyositis-like autoimmunity by the additive expression of AIRE, 第44回日本免疫学会学術集会, Nov. 2015.
120.	Mikiko Takei, Mayo Kondo, Seidai Satou, Hiroshi Kawano, Yuko Toyoda, Masaki Hanibuchi, Yasuhiko Nishioka, Hirokazu Miki, Kumiko Tanaka and Tetsuji Takayama : 好酸球性胆管炎を合併した全身性エリテマトーデスの1例, 第112回日本内科学会四国地方会, Jun. 2015.
121.	Yuko Toyoda, Terumi Takikura, Mayo Kondo, Seidai Satou, Ryohiko Ozaki, Jun Kishi, Toshifumi Tezuka, Hiroshi Kawano, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 膠原病に合併した血球貪食性リンパ組織球症の4症例, 第59回日本リウマチ学会総会・学術集会, Apr. 2015.
122.	Hitoshi Nishijima, Junko Morimoto, Yasuhiro Mouri, Hiroshi Kawano, Koichi Ikuta and Mitsuru Matsumoto : Approaches to identify Aire-regulated non-tissue-restricted antigen genes by the ectopic expression of Aire in thymic cortex, 第43回日本免疫学会学術集会, Dec. 2014.
123.	Hiroshi Kawano, Junko Morimoto, Yasuhiro Mouri, Hitoshi Nishijima, Yasuhiko Nishioka and Mitsuru Matsumoto : Unexpected disturbance of the development of medullary thymic epithelial cells at immature stages by the long-term ablation of mature Aire-expressing cells, 第43回日本免疫学会学術集会, Dec. 2014.
124.	Mayo Kondoh, Seidai Satou, Yuko Toyoda, Jun Kishi, Toshifumi Tezuka, 吉嶋輝実, Masami Kishi, Hiroshi Kawano, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 血小板減少を契機として診断された高齢者のSLEの2例, 第25回日本リウマチ学会中国・四国支部学術集会, Dec. 2014.
125.	松本康平, 尾崎領彦, Yuko Toyoda, Mayuri Nakano, Shun Morizumi, Hiroshi Kawano, Jun Kishi, Souji Kakiuchi, Masaki Hanibuchi and Yasuhiko Nishioka : 高Ca血症にて発症した多臓器サルコイドーシスの1例, 第51回日本呼吸器学会中国・四国地方会, Jul. 2014.
126.	Yuko Toyoda, Jun Kishi, Hiroshi Kawano, Hisatsugu Goto, Masaki Hanibuchi, 中島利博 and Yasuhiko Nishioka : 関節リウマチ患者由来の線維芽細胞様滑膜細胞において thymidine phosphorylaseはCXCL10 を制御する, 第58回日本リウマチ学会総会学術集会, Apr. 2014.
127.	山本聖子, Masaki Hanibuchi, Shun Morizumi, Masami Kishi, Katsuhiro Kinoshita, Hiroshi Kawano, Akio Takezaki, Yuko Toyoda, Momoyo Azuma, Hisatsugu Goto, Jun Kishi and Yasuhiko Nishioka : 左上葉無気肺を呈したアレルギー性気管支肺アスペルギルス症の一例, 第248回徳島医学会, Feb. 2014.
128.	猪子未希, Atsuro Saijo, Masami Kishi, Masaki Hanibuchi, Yoshinori Aono, Yuko Toyoda, Katsuhiro Kinoshita, Toshifumi Tezuka, 吉嶋輝実, Hiroshi Kawano, Jun Kishi, Yasuhiko Nishioka, 池田真由美, Mitsuteru Yoshida, Shoji Sakiyama and 福田悠 : 肺多発浸潤影と胸膜炎を初発症状とした多発性筋炎の1例, 第247回徳島医学会学術集会, Aug. 2013.
129.	Saki Nagase, Yuko Toyoda, Shuichi Abe, Jun Kishi, Hiroshi Kawano, Toshifumi Tezuka, Masaki Hanibuchi, Mayumi Ikeda, Shoji Sakiyama and Yasuhiko Nishioka : サルコイドーシスの経過観察中に肺腺癌を合併した1例, 第49回日本呼吸器学会中国・四国地方会, Jul. 2013.
130.	Shun Morizumi, Kenji Otsuka, Yuko Toyoda, Hiroshi Kawano, Jun Kishi, Toshifumi Tezuka, Terumi Yoshijima, Souji Kakiuchi, Masaki Hanibuchi and Yasuhiko Nishioka : 脳炎と腹部大動脈瘤を合併した多発血管炎性肉芽腫症の1例, 第108回日本内科学会四国地方会, Jun. 2013.
131.	吉嶋輝実, Hiroshi Kawano, Toshifumi Tezuka, Yuko Toyoda, Jun Kishi and Yasuhiko Nishioka : 原因不明の末梢閉塞性動脈疾患加療中に冠動脈瘤が発覚し高安動脈炎と診断した1例., 第57回日本リウマチ学会総会・学術集会, Apr. 2013.
132.	Terumi Yoshijima, Masaki Hanibuchi, Momoyo Azuma, Yuko Toyoda, Hiroshi Kawano, Jun Kishi, Akio Takezaki, Hiroyasu Okazaki, Tamiko Nagao, Reiko Suzuki, Tomoko Takagai, Shoji Sakiyama and Yasuhiko Nishioka : 徳島大学病院職員における潜在性結核感染症の現状, 第63回日本結核病学会中国四国支部会, Feb. 2013.
133.	Hiroshi Kawano, Yuko Toyoda, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : 抗CCP抗体高値を呈し関節炎を伴わずに発症したステロイド抵抗性器質化肺炎の1例, 第23回日本リウマチ学会中国・四国支部学術集会, Oct. 2012.
134.	Mayo Kondo, Yuko Toyoda, Shuichi Abe, Hiroshi Kawano, Masami Kishi, Akio Takezaki, Momoyo Azuma, Souji Kakiuchi, Hisatsugu Goto, Yoshinori Aono, Masaki Hanibuchi and Yasuhiko Nishioka : 病勢に関連してCA19-9の変動を認めた非結核性抗酸菌症の1例, 第20回日本呼吸器内視鏡学会中国四国支部会, Mar. 2012.
135.	矢野祖, 近藤真代, Hiroshi Kawano, Atsuro Saijo, Yuko Toyoda, Souji Kakiuchi, Jun Kishi, Masaki Hanibuchi, Yasuhiko Nishioka, 古川貴大 and Koji Fujita : 神経サルコイドーシスの1例, 第244回徳島医学会学術集会, Feb. 2012.
136.	Hiroyasu Okazaki, Yuko Toyoda, Jun Kishi, Hiroshi Kawano, Souji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi, Masahiko Azuma, Mika Sakaki and Yasuhiko Nishioka : 組織診断が得られた肝サルコイドーシスの2症例, 第22回日本リウマチ学会中国・四国支部学術集会, Dec. 2011.
137.	近藤真代, Hiroshi Kawano, Souji Kakiuchi, Jun Kishi, Masaki Hanibuchi, Masahiko Azuma, 近藤絵里, Masakazu Goda, Naozumi Ishimaru and Yasuhiko Nishioka : IgG4関連下垂体炎の1例, 第105回日本内科学会四国地方会, Nov. 2011.

Et cetera, Workshop:

1.	Hitoshi Nishijima, Tatsuya Kajimoto, Yoshiki Matsuoka, Yasuhiro Mouri, Junko Morimoto, Hiroshi Kawano and Mitsuru Matsumoto : NOD系統特異的に多発性筋炎様症状をもたらすゲノム領域の解析, 第14回四国免疫フォーラム, Jun. 2015.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Development of antifibrotic therapy based on the regulation of lysophospholipid in the pulmonary microenvironment (Project/Area Number: 24K11578 )
Identification of novel profibrotic cell populations using single cell gene expression analysis and its application to the development of molecular targeted drugs (Project/Area Number: 19K08652 )
Novel strategy targeted for fibrocytes migration to treat connective tissue diseases related lung fibrosis (Project/Area Number: 16K21197 )
Search by Researcher Number (30771571)

Designated Associate Professor : Kawano, Hiroshi

Research

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)